Porcine Epidemic Diarrhea Virus

Overview and Taxonomy of Porcine Epidemic Diarrhea Virus

Porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense RNA virus belonging to the genus Alphacoronavirus within the family Coronaviridae, order Nidovirales [5, 7, 12]. This taxonomic placement places PEDV within the same genus as other important coronaviruses, including human coronavirus NL63 (HCoV-NL63) and porcine transmissible gastroenteritis virus (TGEV), though it is distinct from the Betacoronavirus genus which includes SARS-CoV, MERS-CoV, and SARS-CoV-2 [12, 33]. The PEDV virion is pleomorphic, typically spherical, with a diameter of approximately 95–190 nm, and is characterized by the presence of prominent club-shaped spike (S) glycoprotein projections on its surface, which give the virus its characteristic corona-like appearance under electron microscopy [5, 10, 12].

The PEDV genome is approximately 28 kb in length and is organized with a canonical coronavirus genomic structure: a 5′ untranslated region (UTR), a large open reading frame (ORF) 1a/1b encoding non-structural proteins (nsps) that form the replication-transcription complex, followed by structural protein genes encoding the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, and an accessory ORF3 gene interspersed between the S and E genes [7, 12, 30]. The 3′ end of the genome contains a UTR and a poly-A tail [12]. The S protein is a large, type I transmembrane glycoprotein that forms homotrimers on the virion surface and is the primary determinant of viral entry, cell tropism, host range, and a major target for neutralizing antibodies [3, 6, 14, 33]. The M protein is the most abundant envelope component and plays a central role in virion morphogenesis and assembly, while also possessing immunogenic potential and the ability to antagonize host interferon responses [28, 32]. The E protein is a small, integral membrane protein involved in viral assembly, budding, and pathogenesis, and has been identified as a target for host antiviral factors such as KPNA2, which mediates its degradation via selective autophagy [21]. The N protein is a multifunctional, highly immunogenic phosphoprotein that encapsulates the viral RNA genome, is critical for viral replication and transcription, and modulates host cell cycle and immune responses, including interaction with p53 to induce S-phase arrest and suppression of interferon production [27, 34].

Genotypic Classification and Genetic Diversity

The genetic diversity of PEDV has been a subject of intense investigation, driven by the emergence of highly pathogenic variants that have caused devastating outbreaks globally since 2010 [5, 12, 30]. Phylogenetic analysis, particularly of the S gene, has become the cornerstone of PEDV classification, revealing a clear division into two major genotypes: genotype 1 (G1) and genotype 2 (G2) [2, 12, 14]. The G1 genotype, also referred to as classical or conventional strains, includes the prototype strain CV777 (first isolated in Belgium in 1978) and related cell culture-adapted and vaccine strains [5, 12, 38]. Classical G1 PEDV strains are generally considered to be less virulent than contemporary G2 strains and are often associated with milder clinical disease [3, 12]. Within G1, further subdivision into G1a (classical field strains) and G1b (cell culture-adapted and vaccine strains) has been proposed, though the nomenclature is not universally standardized [12, 14].

The G2 genotype encompasses the vast majority of currently circulating field strains worldwide, particularly those responsible for the severe epizootics that began in China in 2010 and subsequently spread to the United States, South Korea, Japan, and many other pig-producing nations [4, 5, 12, 15]. G2 strains are characterized by significant genetic variation in the S gene, including insertions, deletions, and point mutations, particularly within the N-terminal domain (S1-NTD) of the S1 subunit, which is thought to influence receptor binding and antigenicity [3, 12, 19]. Subclassification of G2 strains has evolved over time, with major subgroups designated as G2a, G2b, G2c, and more recently, G2d [8, 17, 22, 24]. G2a strains include early variant isolates from China, such as the highly virulent AJ1102 strain [18, 26, 36]. G2b strains are a broad group that includes many of the pandemic variants, such as those that emerged in the United States in 2013 (e.g., the highly virulent non-S INDEL strains like PC22A and Colorado) [10, 20, 31]. G2c subgroup strains have been identified as predominant circulating variants in China during recent years (2017–2021), as exemplified by the NH-TA2020 isolate [24]. G2d has been proposed as a newly defined subgroup, comprising strains isolated in China from 2017 to 2023 that form an independent phylogenetic branch and possess unique genetic features, including multiple mutations and extensive N-glycosylation patterns in the S protein compared to classical and other G2 strains [22, 24].

The emergence of recombinant PEDV strains further complicates the taxonomic landscape. Natural recombination events, particularly within the S gene and ORF1b, have been documented repeatedly, generating novel variants with altered pathogenicity and antigenic profiles [8, 9, 22]. For instance, strain CH/HLJ/18, a highly pathogenic GII-a recombinant isolated in China, arose from recombination between a BJ-2011-1-like strain and a CH_hubei_2016-like strain, with a breakpoint identified in ORF1b [9]. Similarly, strain PEDV/SC/2022 was identified as a recombinant of AH2012 and AJ1102 [8]. These recombination events underscore the dynamic evolutionary potential of PEDV and the constant emergence of novel genetic lineages that challenge existing control measures.

Virulence Determinants and the Central Role of the Spike Protein

The classification of PEDV into distinct genotypes and subgroups is not merely a taxonomic exercise; it has direct and profound implications for virulence, disease severity, and vaccine efficacy. A seminal study using targeted RNA recombination to generate chimeric PEDVs on an avirulent DR13 vaccine strain background demonstrated unequivocally that the S gene is a primary determinant of virulence [3]. Recombinant viruses carrying the S gene from a highly virulent GDU strain caused severe diarrhea, high viral shedding, and 100% mortality in 3-day-old piglets, whereas those carrying the S gene from a moderately virulent UU strain induced mild to moderate diarrhea with no mortality, and the DR13 S gene conferred a completely non-pathogenic phenotype [3]. This study provided direct experimental evidence that genetic variations in the S protein, even within the same viral backbone, dictate the severity of PEDV-induced disease.

Subsequent research has identified specific genetic signatures within the S protein associated with virulence and attenuation. Serial in vitro and in vivo passage of PEDV leads to the accumulation of mutations and deletions in the S gene, which correlate with reduced virulence, offering insights for live-attenuated vaccine development [11, 18]. Deletions in the S1-NTD, such as the 194–204 amino acid deletions observed in US variants during 2016–2017, and deletions in the carboxy-terminus of the S2 subunit, have been linked to altered pathogenicity and cell tropism [18, 19]. The latter deletion, which also truncates the start codon of ORF3, was shown to attenuate PEDV in piglets while still inducing robust neutralizing antibody responses and protection against challenge, highlighting a potential strategy for rational vaccine design [18]. Furthermore, mutations in the S2′ cleavage site and the fusion peptide region are critical for cell culture adaptation and trypsin-independent growth, which has practical implications for large-scale vaccine production [26, 37]. Three specific amino acid substitutions, A605E, E633Q, and R891G, in the S protein were identified as necessary and sufficient for enabling a cell culture-adapted PEDV strain to efficiently infect Vero cells, likely by altering the S2′ cleavage site and receptor-binding domain structure [37].

Beyond the S protein, other genomic regions contribute to virulence. The non-structural protein 1 (nsp1) is a key antagonist of host interferon responses, and targeted mutations at conserved residues N93 and N95 were shown to attenuate PEDV while retaining immunogenicity, making nsp1 a promising target for live-attenuated vaccine development [29]. The endoribonuclease activity of nsp15 (EndoU) is another critical virulence factor; mutating its catalytic site resulted in a virus that triggered robust type I and III interferon responses and showed significantly reduced shedding and mortality in piglets [31]. The accessory protein ORF3, while playing a more modest role in virulence compared to the S protein, has been implicated in modulating viral pathogenicity, with naturally occurring truncations observed in some field strains [20, 36]. The intricate interplay between these viral proteins, the host innate immune system, and the gut microenvironment dictates the overall pathogenic outcome of PEDV infection and shapes the evolutionary trajectory of the virus.

Global Epidemiology, Transmission, and Economic Impact

The World Organisation for Animal Health (WOAH) recognizes PED as a significant transboundary animal disease with substantial economic consequences for the global swine industry. PEDV is highly contagious and can affect pigs of all ages, but the most severe disease, characterized by acute watery diarrhea, vomiting, dehydration, and mortality rates approaching 100%, occurs in neonatal piglets under one week of age [1, 5, 10]. The virus is transmitted primarily via the fecal-oral route, but aerosolized virus, contaminated fomites, feed, and transportation vehicles also play crucial roles in between-farm and long-distance spread [2, 35]. Mathematical modeling of between-farm transmission dynamics in the United States estimated that 42.7% of sow farm infections were attributable to feed delivery vehicles, while 34.5% of nursery infections were linked to pig transport vehicles, underscoring the critical importance of biosecurity and logistics in disease control [35]. Phylogeographic analyses have further revealed that the provinces of Guangdong and Henan in China served as major hubs for the national and global dissemination of PEDV, with live swine trade identified as a primary driver of viral spread both within China and internationally, particularly from the United States to Japan, Korea, and Mexico [25].

Since the emergence of highly pathogenic G2 variants in China in 2010, PEDV has become a global pandemic threat. The virus was first detected in the United States in April 2013, where it spread with unprecedented rapidity, causing the death of an estimated 7–8 million piglets within the first year, representing losses of billions of dollars to the US swine industry [10, 35]. Subsequently, highly virulent PEDV strains were introduced into South Korea, Japan, Taiwan, and many other countries, causing recurrent epidemics and endemic persistence [15, 25]. In South Korea, endemic PED in farrow-to-finish herds is perpetuated by long-term virus survival in slurry and the presence of asymptomatically infected replacement gilts (“Trojan pigs”), which can introduce the virus into farrowing houses and trigger year-round outbreaks [15]. Epidemiological surveillance in China over the past decade has consistently demonstrated a high prevalence of PEDV, with detection rates in diarrheic piglets ranging from 25.93% in Yunnan Province (2013–2022) to over 63% in farm-level surveys across multiple provinces (2017–2021) [4, 24]. Co-infections are common, with PEDV frequently co-detected alongside porcine kobuvirus (PKV), porcine rotavirus (PoRV), porcine deltacoronavirus (PDCoV), and Clostridium perfringens type A, often resulting in enhanced disease severity and complicating diagnosis and treatment [4, 13, 16, 23]. The continuous evolution of PEDV, driven by high mutation rates, recombination, and selective pressure from host immunity and vaccination, ensures that new variant strains will continue to emerge, posing an ongoing challenge to global pig health and food security.

Genomic Organization and Genetic Diversity of PEDV

The genomic architecture of the Porcine Epidemic Diarrhea Virus (PEDV) is a paradigm of the Alphacoronavirus genus within the Coronaviridae family, characterized by a single-stranded, positive-sense RNA genome of approximately 28 kilobases (kb). This genome is organized with a canonical coronavirus structure: a 5′ cap, a 5′ untranslated region (UTR), a large open reading frame (ORF) 1a/1b encoding non-structural proteins (nsps), followed by the structural protein genes in the order spike (S), envelope (E), membrane (M), and nucleocapsid (N), interspersed with accessory genes, and terminating in a 3′ UTR with a polyadenylated tail [2, 5, 7]. The precise genetic organization is not merely a static blueprint but a dynamic scaffold that underpins the virus’s remarkable capacity for evolution, immune evasion, and pathogenesis. The ORF1a and ORF1b, which comprise roughly two-thirds of the genome, are translated into two large polyproteins (pp1a and pp1ab) via a ribosomal frameshift mechanism. These polyproteins are subsequently cleaved by viral proteases into 16 non-structural proteins (nsp1–nsp16), which assemble into the replication-transcription complex (RTC) [7, 41]. These nsps are not merely enzymatic workhorses; they are sophisticated antagonists of host innate immunity. For instance, nsp1 is a potent inhibitor of host gene expression and interferon (IFN) responses, with specific residues like N93 and N95 being critical for this antagonistic function. Mutations at these sites have been shown to attenuate the virus by rendering it more sensitive to the host IFN response, highlighting a direct link between genomic sequence, protein function, and virulence [29]. Similarly, nsp7, a component of the RTC, has been demonstrated to antagonize IFN signaling through multiple mechanisms, including inhibiting MDA5 dephosphorylation to block type I IFN production [41] and sequestering the interaction between KPNA1 and STAT1 to prevent JAK-STAT signaling [42]. The endoribonuclease activity of nsp15 (EndoU) is another critical virulence factor, as its activity is essential for suppressing both type I and type III IFN responses in infected epithelial cells and macrophages, thereby facilitating viral replication and pathogenesis in vivo [31]. This intricate network of immune evasion strategies, encoded directly within the genomic organization, underscores the evolutionary arms race between PEDV and its porcine host.

The structural proteins, while essential for virion architecture and entry, are also major drivers of genetic diversity. The S glycoprotein, a large class I fusion protein that forms the characteristic corona on the virion surface, is the most variable and immunologically critical component [2, 3, 6]. The S protein is functionally divided into the S1 subunit, responsible for receptor binding, and the S2 subunit, which mediates membrane fusion. The S1 subunit, particularly its N-terminal domain (S1-NTD), is a hotspot for genetic variation, including insertions, deletions, and point mutations, which directly impact antigenicity, cell tropism, and virulence [6, 14, 19]. The membrane (M) protein, the most abundant envelope component, plays a central role in virus assembly and morphogenesis. Beyond its structural role, the M protein is a potent IFN antagonist, interacting with the inhibitory domain of IRF7 to suppress its phosphorylation and dimerization, thereby inhibiting type I IFN production [32]. The N protein, which encapsulates the viral RNA, is a multifunctional phosphoprotein involved in RNA replication, transcription, and translation. It also serves as a major antagonist of the host cell cycle, inducing S-phase arrest by interacting with p53 and activating the p53-DREAM pathway, a manipulation that creates a favorable cellular environment for viral replication [27]. The accessory protein ORF3, while not essential for viral replication in vitro, has been implicated in virulence and pathogenesis in vivo, though its exact role remains nuanced. Studies using reverse genetics have shown that an intact ORF3 has a modest impact on pathogenicity, while its deletion can contribute to attenuation, making it a target for live-attenuated vaccine development [18, 20]. However, naturally occurring PEDV strains with a truncated ORF3 have been isolated and shown to retain high virulence, indicating that the relationship between ORF3 and pathogenicity is complex and strain-dependent [36].

The genetic diversity of PEDV is most profoundly manifested in the S gene, which forms the basis for the current genotyping system. PEDV strains are broadly classified into two major genotypes: G1 (classical) and G2 (variant/epidemic). The G1 genotype includes the prototype CV777 strain and its attenuated vaccine derivatives, while the G2 genotype encompasses the highly virulent variants that have caused devastating outbreaks globally since 2010 [2, 5, 12]. The G2 genotype is further subdivided into subgroups G2a, G2b, G2c, and a more recently defined G2d, based on phylogenetic analysis of the complete S gene or its S1 region [4, 8, 22]. This classification is not merely taxonomic; it reflects significant differences in virulence, antigenicity, and epidemiological fitness. For instance, the G2b subgroup has been widely associated with the severe outbreaks in North America and Asia, while G2c strains have become predominant in China in recent years [8, 24]. The G2d subgroup, which forms an independent branch containing strains isolated from 2017 onwards, exhibits multiple unique mutations and extensive N-glycosylation patterns compared to classical strains, suggesting ongoing antigenic drift [22]. The non-S INDEL (insertion/deletion) strains, which lack the characteristic insertions and deletions in the S gene compared to classical strains, are generally highly virulent, whereas S INDEL strains, which possess these genetic signatures, often cause milder disease [10]. This correlation between S gene sequence and virulence has been experimentally validated using reverse genetics. Recombinant PEDVs (rPEDVs) engineered to carry the S gene from a highly virulent GDU strain, within the genetic background of an avirulent DR13 vaccine strain, caused severe diarrhea and high mortality in piglets. Conversely, rPEDVs carrying the S gene from a moderately virulent UU strain induced only mild symptoms, while those with the DR13 S gene were non-pathogenic [3]. This unequivocally demonstrates that the S protein is a primary determinant of PEDV virulence.

The mechanisms driving this genetic diversity are multifaceted, with recombination and point mutations being the primary engines. PEDV, like all coronaviruses, has a high mutation rate due to the lack of proofreading activity in its RNA-dependent RNA polymerase (RdRp), although the presence of an exoribonuclease (nsp14) provides some fidelity. This results in a continuous accumulation of single nucleotide polymorphisms (SNPs), particularly in the hypervariable regions of the S gene [11, 14]. The evolutionary rate of the S gene has been shown to be significantly higher than that of the ORF3 gene, and serial passage of PEDV in vitro and in vivo accelerates this rate, leading to the emergence of amino acid changes and reduced N-linked glycosylation that can alter antigenicity and attenuate virulence [11]. Homologous recombination, a hallmark of coronavirus evolution, is another powerful force shaping PEDV diversity. Co-infection of a single host with multiple PEDV strains, or even with other coronaviruses, provides the substrate for recombination events during RNA replication. Numerous recombinant PEDV strains have been identified and characterized. For example, the highly pathogenic GII-a strain CH/HLJ/18 was identified as a recombinant of PEDV BJ-2011-1 and PEDV CH_hubei_2016, with a breakpoint located in ORF1b [9]. Similarly, the isolate PEDV/SC/2022 was shown to originate from recombination between PEDV/AH2012 and PEDV/AJ1102 [8]. These recombination events can rapidly generate novel genotypes with altered pathogenic and antigenic profiles, potentially leading to immune escape from existing vaccines. The emergence of PEDV variants with large deletions in the S1-NTD, such as the 194-204 amino acid deletions identified in the US and Japan, further exemplifies the virus’s capacity for dramatic genetic change, which may be associated with altered disease patterns and cell tropism [19].

The practical implications of this genetic diversity are profound, particularly for disease control and vaccine efficacy. The classical GI-based vaccines, such as those derived from the CV777 strain, have been shown to provide insufficient protection against the emerging GII variant strains, a major factor contributing to the failure to control PEDV globally [5, 12]. The antigenic drift in the S protein, especially within neutralizing epitopes in the S1 domain, allows variant strains to evade antibodies elicited by classical vaccines. This has necessitated the development of new vaccine strategies, including the use of current G2 field strains as vaccine candidates, the engineering of recombinant vaccines with chimeric S proteins, and the development of novel platforms like mRNA and viral-vector vaccines [2, 26, 39]. The genetic diversity also complicates molecular diagnostics. While PCR-based methods targeting conserved genes like the N or M gene are generally reliable, the high variability of the S gene means that primer and probe sets must be continuously monitored and updated to ensure they can detect all circulating variants [16, 40, 43]. The World Organisation for Animal Health (WOAH) recognizes PED as a significant transboundary animal disease, and the genetic characterization of circulating strains is a cornerstone of effective surveillance and control programs. The phylogeographic analysis of PEDV has revealed that live swine trade is a major driver of its global spread, with China and the United States acting as primary hubs for the dissemination of new lineages [25]. This underscores the need for coordinated international surveillance efforts to track the emergence and spread of novel genetic variants, which is essential for informing vaccine updates and implementing effective biosecurity measures.

Molecular Pathogenesis and Host-Virus Interactions

The pathogenesis of Porcine Epidemic Diarrhea Virus (PEDV) is a multifaceted process orchestrated by a sophisticated interplay between viral virulence determinants and host cellular machinery. This interaction dictates the outcome of infection, ranging from subclinical enteric colonization to catastrophic, near-total mortality in neonatal piglets. The molecular basis of this disease is rooted in the virus’s ability to hijack host cell processes for replication while simultaneously subverting the innate immune defenses that would otherwise control the infection. The following analysis dissects these complex interactions, focusing on the roles of viral structural and non-structural proteins, the mechanisms of immune evasion, and the host factors that either restrict or facilitate viral propagation.

The Spike Glycoprotein: The Master Determinant of Virulence and Cellular Tropism

The spike (S) glycoprotein is the most critical structural protein in PEDV pathogenesis, serving as the primary determinant of viral entry, cell tropism, and virulence. The S protein is a large, trimeric class I fusion protein that mediates receptor binding and membrane fusion. Elegant reverse genetics studies have unequivocally demonstrated that the S gene is the principal virulence factor. When the S gene from a highly virulent GII strain (e.g., GDU) was placed into the genetic background of the avirulent DR13 vaccine strain, the resulting recombinant virus caused severe diarrhea, high viral shedding, and mortality in 3-day-old piglets. Conversely, a recombinant carrying the S gene from a moderately virulent strain (UU) induced only mild to moderate disease, while the parental DR13 S gene conferred a non-pathogenic phenotype [3]. This confirms that the S protein is not merely a facilitator of entry but a primary driver of in vivo pathogenicity.

The molecular basis for this virulence lies in the S protein’s structure and its interaction with host cell receptors. The S1 subunit contains the receptor-binding domain (RBD), which engages host receptors such as porcine aminopeptidase N (pAPN). However, the interaction is more complex, as PEDV can also utilize other co-receptors or alternative entry pathways. For instance, heat shock protein family A member 5 (HSPA5) has been identified as a novel host factor that interacts with the S1 protein to promote viral attachment and internalization via the endo-/lysosomal pathway [48]. Furthermore, the S2 subunit, which mediates membrane fusion, contains a fusion peptide (FP) and a second proteolytic cleavage site (S2′). Mutations in these regions are critical for cell adaptation and virulence. Specifically, three amino acid substitutions (A605E, E633Q, and R891G) in the S protein of a cell-adapted strain were found to be essential for productive infection of Vero cells, likely by altering the S2′ cleavage site and RBD structure [37]. The S protein’s extensive genetic variability, particularly in the S1 N-terminal domain (NTD), leads to the emergence of variants with large deletions (e.g., 194-204 amino acid deletions) that can alter antigenicity and potentially modulate virulence [19]. The S protein is also the primary target for neutralizing antibodies, and its continuous evolution, especially in the GII genotype, explains why vaccines based on classical GI strains (e.g., CV777) fail to provide adequate protection against contemporary field strains [2, 5, 6].

Non-Structural Proteins: Architects of Immune Evasion and Replication

PEDV encodes a suite of non-structural proteins (nsps) derived from the proteolytic cleavage of the large polyproteins pp1a and pp1ab. These nsps are not merely components of the replication-transcription complex (RTC); they are potent antagonists of the host innate immune response, particularly the interferon (IFN) system.

nsp1 is a well-conserved alphacoronavirus protein that acts as a global inhibitor of host gene expression and a potent IFN antagonist. Mutations in nsp1, specifically at residues N93 and N95, render the virus highly sensitive to IFN responses and significantly attenuate virulence in vivo. A recombinant PEDV carrying these mutations (N93/95A) triggered stronger type I and III IFN responses, replicated to lower titers, and caused minimal mortality in piglets while still conferring protective immunity upon challenge [29]. This highlights nsp1 as a critical virulence factor and a promising target for live-attenuated vaccine development.

nsp7 is another multifunctional nsp that plays a dual role in antagonizing the IFN response. First, it inhibits the production of type I IFN by targeting melanoma differentiation-associated gene 5 (MDA5). PEDV nsp7 interacts with the caspase activation and recruitment domains (CARDs) of MDA5, preventing the protein phosphatase 1 (PP1)-mediated dephosphorylation of MDA5 at S828. This keeps MDA5 in an inactive state, thereby blocking the downstream activation of IRF3 and NF-κB and suppressing IFN-β production [41]. Second, nsp7 also antagonizes IFN-α-induced JAK-STAT signaling. It achieves this by interacting with the DNA-binding domain of STAT1 and STAT2, which sequesters the interaction between karyopherin α1 (KPNA1) and STAT1, thereby blocking the nuclear translocation of the ISGF3 complex and preventing the expression of interferon-stimulated genes (ISGs) [42].

nsp13 (helicase) and EndoU (endoribonuclease) are additional viral proteins that contribute to immune evasion. nsp13 interacts with heterogeneous nuclear ribonucleoprotein U (HNRNPU), a host RNA sensor. This interaction retains HNRNPU in the cytoplasm and upregulates its expression. HNRNPU then promotes PEDV replication by degrading TRAF3 mRNA in an m6A-dependent manner via the METTL3-METTL14/YTHDF2 axis, thereby inhibiting IFN-β production [50]. The EndoU activity of PEDV is a key virulence factor that suppresses both type I and type III IFN responses in porcine epithelial cells and macrophages. A mutant virus lacking EndoU activity (icPEDV-EnUmt) induced robust IFN responses, leading to restricted replication in vitro and reduced viral shedding and mortality in piglets [31].

The Nucleocapsid Protein: A Nexus of Viral Replication and Host Cell Cycle Manipulation

The nucleocapsid (N) protein is the most abundant viral protein and is essential for encapsidating the viral RNA genome. Beyond its structural role, the N protein is a central hub for virus-host interactions. It subverts the host cell cycle to create a favorable environment for viral replication. PEDV N protein induces S-phase arrest in infected cells by interacting with the tumor suppressor p53. This interaction maintains high levels of p53 expression, which activates the p53-DREAM pathway, leading to cell cycle arrest. This arrest is dependent on a specific nuclear localization signal (S71NWHFYYLGTGPHADLRYRT90) and a p53-interacting domain (NS171–N194) within the N protein. Importantly, S-phase arrest was shown to significantly promote viral replication [27].

The N protein is also a target for host antiviral factors that attempt to restrict infection. A growing family of host proteins, including TARDBP, FUBP3, hnRNP K, PRPF19, RALY, and PTBP1, have been shown to inhibit PEDV replication by targeting the N protein for degradation via selective autophagy [34, 58, 60-63]. These host factors typically recruit an E3 ubiquitin ligase (e.g., MARCH8) to ubiquitinate the N protein, which is then recognized by a cargo receptor (e.g., NDP52) and delivered to autolysosomes for destruction. Concurrently, many of these same factors (e.g., TARDBP, FUBP3, hnRNP K) also activate the type I IFN signaling pathway, often through upregulation of MyD88 and TRAF3, providing a dual mechanism of antiviral defense [34, 60, 61]. Conversely, PEDV can hijack host proteins to protect its N protein. For example, the virus upregulates TRIM28, an E3 ubiquitin ligase that interacts with the N protein to induce mitophagy. This mitophagy-mediated degradation of mitochondria inhibits the JAK-STAT1 pathway, thereby suppressing the IFN response and promoting viral replication [47].

Cellular Stress, Inflammatory Signaling, and Cell Death Pathways

PEDV infection profoundly disrupts cellular homeostasis, triggering stress responses that the virus manipulates to its advantage. Infection activates the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Specifically, PEDV activates the PERK/eIF2α pathway, leading to the expression of the pro-apoptotic protein CHOP and ER oxidoreductase 1 alpha (ERO1α). This PERK-CHOP-ERO1α axis generates reactive oxygen species (ROS), which are essential for efficient viral replication. Inhibition of any component of this pathway (PERK, CHOP, ERO1α, or ROS) significantly suppresses PEDV replication, indicating that the virus actively manipulates ER stress and oxidative stress to create a permissive environment [51].

PEDV also induces a potent inflammatory response. The virus triggers the release of mitochondrial DNA (mtDNA) from damaged mitochondria, which activates the NLRP3 inflammasome, leading to the secretion of IL-1β [46]. Furthermore, PEDV infection promotes the accumulation of lipid droplets (LDs) and upregulates the chemokine IL-8. IL-8, in turn, elevates cytosolic Ca2+ levels via the GPCR-PLC-IP3R-SOC signaling pathway, which facilitates viral internalization and egress [52]. The virus also activates the NF-κB signaling pathway, leading to the production of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α [59]. While these inflammatory responses are part of the host defense, their dysregulation contributes to the severe intestinal pathology and villous atrophy characteristic of PED.

The interplay between cell death pathways is also critical. PEDV can induce apoptosis, necroptosis, and ferroptosis. The virus-induced ROS production and p53 activation drive apoptosis [64]. Interestingly, the host can exploit cell death pathways for defense. For instance, the ferroptosis activator RSL3 inhibits PEDV replication, while the ferroptosis inhibitor N-acetylcysteine promotes it, suggesting that ferroptosis is a host antiviral mechanism [55, 57]. Conversely, PEDV-induced necroptosis, mediated by the RIPK1-RIPK3-MLKL signaling axis, is a pathological process that the host can counteract. The gut commensal Faecalibacterium prausnitzii and its outer membrane vesicles (OMVs) have been shown to alleviate PEDV infection by increasing phosphatidylcholine (PC) levels, which in turn reduces necroptosis in intestinal epithelial cells [1].

Host Restriction Factors and the Intestinal Microenvironment

The host has evolved multiple layers of defense beyond the IFN system. As discussed, numerous RNA-binding proteins (e.g., RBM14, PTBP1, TARDBP) and nuclear proteins (e.g., KPNA2) act as restriction factors. RBM14, for example, recruits the cargo receptor p62 to degrade the N protein via autophagy and also interacts with MAVS to induce IFN expression [45]. KPNA2 suppresses PEDV by targeting and degrading the viral envelope (E) protein through selective autophagy [21].

The intestinal microenvironment, including the gut microbiota and its metabolites, plays a crucial role in modulating PEDV pathogenesis. Short-chain fatty acids (SCFAs) like butyrate, produced by gut bacteria, limit PEDV replication in intestinal epithelial cells by activating GPR43, which enhances the production of type III IFN (IFN-λ) [53]. Probiotics such as Lactobacillus rhamnosus GG (LGG) can alleviate PEDV-induced intestinal injury by improving antioxidant capacity and modulating inflammatory pathways [44]. Furthermore, milk-derived small extracellular vesicles (sEVs) and their cargo miRNAs (e.g., miR-let-7e and miR-27b) have been shown to inhibit PEDV infection by targeting the viral N protein and host HMGB1 [49]. These findings underscore the importance of the gut ecosystem in determining the outcome of PEDV infection and highlight potential probiotic and nutritional interventions for disease control.

Co-infection Dynamics and Cross-Species Potential

In the field, PEDV rarely acts alone. Co-infections with other enteric pathogens, such as porcine kobuvirus (PKV), Clostridium perfringens type A (CPA), and transmissible gastroenteritis virus (TGEV), are common and can dramatically alter disease severity. Co-infection with PKV enhances PEDV replication and exacerbates intestinal pathology and clinical symptoms [13]. Similarly, co-infection with CPA promotes PEDV replication and leads to more severe villous atrophy and diarrhea than either pathogen alone [23]. These synergistic interactions complicate diagnosis, treatment, and control strategies.

Of significant concern is the potential for PEDV to cross species barriers. While PEDV is primarily a swine pathogen, it has been shown to replicate in human small intestinal epithelial cells (FHs 74 Int cells) in vitro, with a virulent GII strain (LJX) demonstrating infectivity while a classical GI strain (CV777) did not [56]. This finding, combined with the virus’s extensive cell tropism and the ability of its S protein to adapt to different receptors [54], raises the possibility of zoonotic transmission, underscoring the need for continued surveillance and a One Health approach to managing this economically devastating pathogen.

Epidemiology and Global Distribution of PEDV

Porcine Epidemic Diarrhea Virus (PEDV) represents one of the most economically devastating enteric pathogens confronting the global swine industry, with its epidemiological footprint expanding dramatically over the past two decades. The virus, an enveloped, single-stranded positive-sense RNA virus belonging to the genus Alphacoronavirus within the family Coronaviridae, has transitioned from a regional concern to a truly global pandemic pathogen, causing catastrophic losses in pig-producing nations across Asia, the Americas, and Europe [2, 5, 12]. Understanding the intricate patterns of PEDV emergence, dissemination, and genetic diversification is paramount for designing effective surveillance, prevention, and control strategies. The World Organisation for Animal Health (WOAH) recognizes PED as a significant transboundary animal disease, underscoring its impact on international swine health and trade.

Historical Emergence and the Paradigm Shift of 2010

The epidemiological history of PEDV can be demarcated into two distinct eras: the pre-2010 period characterized by sporadic, relatively mild outbreaks, and the post-2010 era defined by the emergence of highly pathogenic (HP) variant strains. PEDV was first identified in the United Kingdom in 1971 and subsequently reported in several European countries, where it caused mild enteric disease in fattening pigs and sows, with negligible mortality in neonatal piglets [5, 12]. The prototype strain, CV777, isolated in Belgium in 1978, became the reference for classical genotype 1 (GI) strains. These early GI strains were generally of low virulence and were effectively controlled through management practices and early vaccination efforts.

The epidemiological landscape was irrevocably altered in October 2010 when severe outbreaks of acute diarrhea and vomiting with 80–100% mortality in neonatal piglets erupted in southern China, particularly in Guangdong Province [5, 12, 25]. These outbreaks were caused by novel, highly virulent variant strains that were genetically distinct from the classical CV777-like strains. Phylogenetic analyses classified these emerging strains as genotype 2 (GII), which rapidly supplanted the GI strains across China and subsequently spread globally [2, 12]. This re-emergence was not a singular event but a fundamental shift in viral pathogenicity and transmissibility. The GII strains, particularly the GIIa and GIIb subgroups, were characterized by significant genetic diversity in the spike (S) glycoprotein gene, including insertions, deletions, and point mutations that enhanced their virulence and ability to evade pre-existing immunity induced by classical vaccines [3, 5, 6]. The S protein, being the primary determinant of viral attachment, entry, and a major target for neutralizing antibodies, became the central focus for understanding this epidemiological transformation [3, 6]. Studies using reverse genetics have unequivocally demonstrated that the S gene from highly virulent GII strains, when placed into the genetic background of an avirulent GI vaccine strain, is sufficient to confer severe diarrhea and high mortality in piglets, directly linking S gene variability to virulence [3].

Global Dissemination and Phylogeographic Patterns

Following the emergence of HP-GII PEDV in China, the virus exhibited a remarkable capacity for rapid transcontinental spread, driven largely by the international trade of live swine and contaminated swine products [25]. In April 2013, PEDV was detected for the first time in the United States, where it spread with unprecedented speed, infecting an estimated 50% of the US sow herd within one year and causing the death of over 7 million piglets [10, 25]. Phylogeographic analyses have identified the United States as a major secondary hub for global dissemination, from which the virus was subsequently introduced into Canada, Mexico, Japan, South Korea, and several other countries [25]. This pattern highlights the critical role of the US swine industry in the global amplification of the pandemic.

The genetic characterization of US PEDV isolates revealed the co-circulation of two major pathotypes: the highly virulent non-S INDEL (insertion/deletion) strains, which were closely related to the Chinese HP-GII strains, and the less virulent S INDEL strains, which possessed insertions and deletions in the S gene and caused milder clinical disease [10]. The S INDEL strains, first identified in the US in early 2014, were likely introduced independently from a different source population and exhibited reduced pathogenicity, with lower mortality rates and less severe diarrhea [10]. This dichotomy between non-S INDEL (highly virulent) and S INDEL (moderately virulent) strains has persisted and is now recognized as a key feature of global PEDV epidemiology. In the United States, continued surveillance from 2016–2017 identified novel PEDV variants with large deletions in the N-terminal domain (NTD) of the S1 subunit, including deletions of 194, 201, 202, and 204 amino acids, which were often found co-infecting pigs alongside the original US PEDV strains [19]. The emergence of these S1 NTD-del variants suggests ongoing viral evolution and adaptation within the US swine population, potentially altering disease patterns and complicating diagnostic efforts.

In Asia, the epidemiological situation remains highly dynamic. In China, the epicenter of the pandemic, PEDV has become endemic, with continuous circulation and evolution of multiple GII sub-lineages. Longitudinal studies from Yunnan Province, spanning 2013 to 2022, reported an overall PEDV detection rate of 25.93% (480/1851) in diarrheic samples, with all 28 sequenced epidemic strains classified as GII variants [4]. The prevalence was highest in spring (61.52%) and lowest in summer (12.68%), and weaned piglets were found to be more susceptible than fattening pigs [4]. A broader national survey from 2017 to 2021, encompassing 882 samples from 303 farms, revealed a farm-level positivity rate of 52.15% and a sample-level detection rate of 63.95% [24]. Phylogenetic analysis of the S1 gene from 104 strains demonstrated that the GIIc subgroup was the predominant circulating branch, while a newly defined G2d subgroup was also identified in three provinces [24]. The G2d subgroup, which forms an independent branch containing strains isolated from 2017 to 2023, has been characterized by multiple mutations and extensive N-glycosylation changes in the S protein compared to the CV777 vaccine strain [22]. Recombination events are a major driver of PEDV genetic diversity in China. A recombinant PEDV strain, CH/HLJ/18, belonging to the GIIa subgroup, was identified as a recombinant of strains BJ-2011-1 and CH_hubei_2016, with a breakpoint in ORF1b [9]. Similarly, strain PEDV/SC/2022 was found to be a recombinant of PEDV/AH2012 and PEDV/AJ1102 [8]. These recombinant viruses often exhibit unique amino acid deletions and mutations in the S protein, leading to altered antigenicity and pathogenicity, and they pose a significant challenge to vaccine efficacy [9, 22].

South Korea has also experienced significant PEDV epidemics since the 1990s, with the virus becoming endemic in many farrow-to-finish herds [15]. The endemic persistence of PEDV in Korean farms is characterized by year-round recurrent outbreaks, driven by long-term virus survival in slurry and the presence of asymptomatically infected gilts, termed “Trojan Pigs,” which can reintroduce the virus into farrowing houses [15]. This endemic cycle highlights the difficulty of eradication once the virus is established in a region with high pig density and continuous production flows.

Transmission Dynamics and Risk Factors

PEDV is transmitted primarily via the fecal-oral route, but the virus can also spread through multiple other pathways, including airborne aerosols, contaminated fomites, feed, and transportation vehicles [2, 10, 35]. The role of between-farm transmission networks has been rigorously modeled, revealing that the relative importance of different routes varies by farm type. In sow farms, vehicles transporting feed were estimated to account for 42.7% of infections, while in nursery farms, vehicles transporting pigs between sites were the dominant route (34.5%) [35]. Local transmission via farm-to-farm proximity was the most significant route for finisher farms (31.4%) [35]. These findings underscore the critical importance of biosecurity measures targeting feed delivery and pig transport logistics. The contribution of feed ingredients, such as animal by-products, was found to be negligible in transmission models, suggesting that contamination of feed ingredients is not a primary driver of between-farm spread [35].

The virus is remarkably stable in the environment, particularly in liquid manure, where it can remain infectious for extended periods, facilitating indirect transmission [15]. Airborne transmission via the fecal-nasal route has also been demonstrated, with PEDV RNA detected in air samples from infected barns, indicating that aerosolized virus can contribute to within-farm and potentially between-farm spread under certain conditions [10].

Co-infections and Syndemic Interactions

PEDV rarely circulates in isolation; co-infections with other enteric pathogens are the norm rather than the exception, and these interactions can significantly alter disease severity and epidemiology. In Yunnan Province, China, dual infections were identified in 2.81% of samples, with PEDV + porcine Sapovirus (PoSaV) being the most common combination, followed by PEDV + porcine Rotavirus (PoRV) [4]. In a study using a multiplex qPCR for swine enteric coronaviruses in China, the co-infection rate of PEDV with porcine Deltacoronavirus (PDCoV) was alarmingly high at 23.16%, and triple infections with PEDV, TGEV, and PDCoV were found in 11.90% of samples [16]. These high rates of co-infection create opportunities for viral recombination and complicate clinical diagnosis and management.

The pathogenic consequences of co-infection can be profound. Co-infection of piglets with PEDV and porcine Kobuvirus (PKV) resulted in more severe clinical symptoms, acute gastroenteritis, and higher PEDV replication compared to infection with PEDV alone [13]. Similarly, co-infection with PEDV and Clostridium perfringens type A (CPA) in weaned pigs led to significantly more severe diarrheal signs and higher PEDV fecal titers than single infections, indicating a synergistic effect that enhances disease severity [23]. These syndemic interactions highlight the need for comprehensive diagnostic approaches that can detect multiple pathogens simultaneously, as focusing solely on PEDV may underestimate the true disease burden and lead to ineffective control measures.

Genetic Diversity and the Role of the Spike Protein in Epidemiology

The extraordinary genetic plasticity of PEDV, particularly within the S gene, is the primary driver of its epidemiological success. The S protein is not only the key determinant of virulence and cell tropism but also the main target of the host immune response [3, 6, 54]. The continuous emergence of new genetic variants, including GIIa, GIIb, GIIc, and the newly defined G2d subgroups, reflects ongoing selective pressure from host immunity and vaccination [2, 22, 24]. The S gene is divided into the S1 domain, which contains the receptor-binding domain (RBD) and is responsible for host cell attachment, and the S2 domain, which mediates membrane fusion [6]. Mutations in the S1 NTD and RBD can alter receptor binding affinity and antigenicity, allowing the virus to escape neutralizing antibodies induced by previous infection or vaccination [3, 6, 14]. For instance, the emergence of S1 NTD-del variants in the US with large deletions suggests that the virus can tolerate significant structural changes in this region, potentially altering its interaction with host receptors and immune surveillance [19].

The S2 domain is also critical for virulence. Studies using reverse genetics have shown that deletions in the carboxy-terminus of the S2 gene, combined with the loss of the ORF3 start codon, can attenuate PEDV in vivo, while the S1 deletion alone only partially reduces virulence [18]. Furthermore, specific amino acid substitutions in the S2 subunit, such as 803L and 976H, are essential for PEDV adaptation to Vero cells, highlighting the role of S2 in cell tropism and host range [54]. The ability of PEDV to infect human small intestinal epithelial cells (FHs 74 Int cells) in vitro, as demonstrated with the LJX strain but not the CV777 strain, raises the concerning possibility of cross-species transmission, although no zoonotic events have been documented to date [56]. This potential, however, underscores the need for continued surveillance at the animal-human interface.

Global Prevalence and Regional Variations

The prevalence of PEDV varies significantly by region, production system, and season. In China, detection rates in diarrheic samples range from 25% to over 60%, depending on the study and geographic location [4, 24]. In the United States, after the initial devastating epidemic, PEDV has become endemic in many herds, with periodic outbreaks driven by lapses in biosecurity and the introduction of naïve gilts. In Europe, PEDV has been reported in several countries, but the prevalence is generally lower than in Asia and the Americas, likely due to differences in production systems and biosecurity practices. The virus continues to be detected in South Korea, Japan, and other Asian countries, where it remains a major cause of neonatal diarrhea [15].

The economic impact of PEDV is staggering. The Food and Agriculture Organization (FAO) has highlighted PED as a major threat to global food security, particularly in regions where smallholder pig production is critical for livelihoods. The high mortality in neonatal piglets, combined with the costs of biosecurity, vaccination, and lost production, places an immense burden on the swine industry worldwide. The continuous evolution of the virus, driven by its error-prone RNA-dependent RNA polymerase and the selective pressure of widespread vaccination, ensures that PEDV will remain a formidable challenge for the foreseeable future.

Advanced Diagnostic and Detection Methods for PEDV

The accurate, rapid, and cost-effective detection of Porcine Epidemic Diarrhea Virus (PEDV) is a cornerstone of effective disease surveillance, outbreak management, and the evaluation of intervention strategies, including vaccination protocols. The substantial economic burden imposed by PEDV on the global swine industry, coupled with its high morbidity and mortality in neonatal piglets, necessitates a diagnostic armamentarium that extends beyond basic clinical observation. As Zhuang et al. note, molecular detection methods, including PCR-based techniques, isothermal amplification assays, immunological assays, and biosensors, play an indispensable role in the diagnosis and monitoring of PEDV [2]. The genetic diversity of circulating strains, particularly within the spike (S) gene, further complicates diagnostics, as assays must maintain sensitivity and specificity across evolving viral genotypes [3, 6]. This section provides a deep, exhaustive analysis of the advanced diagnostic and detection methodologies currently employed for PEDV, ranging from gold-standard nucleic acid amplification tests (NAATs) to cutting-edge CRISPR-based platforms and novel host-response biomarkers.

Nucleic Acid Amplification Tests (NAATs): The Molecular Cornerstone

Reverse transcription polymerase chain reaction (RT-PCR) and its real-time quantitative variant (RT-qPCR) remain the most widely adopted and authoritative molecular tools for PEDV detection, recognized by international bodies such as the World Organisation for Animal Health (WOAH). These methods offer exceptional sensitivity and specificity, capable of detecting viral RNA in fecal samples, intestinal tissues, and environmental specimens even at low viral loads. The fundamental targets for these assays are often the highly conserved nucleocapsid (N) and membrane (M) genes, although the S gene is also frequently employed for genotyping purposes [16, 40, 71]. The development of multiplex qRT-PCR assays has been a significant advancement, enabling the simultaneous differential diagnosis of PEDV from other enteric pathogens that present with nearly identical clinical signs, such as transmissible gastroenteritis virus (TGEV), porcine deltacoronavirus (PDCoV), and porcine rotavirus A (PoRVA) [16, 40, 71]. For instance, Chen et al. developed a multiplex qPCR targeting the PEDV M gene, TGEV S gene, and PDCoV N gene, achieving a detection limit of 10 copies/μL without cross-reactivity to other common porcine viruses [16]. Similarly, a triplex qRT-PCR reported by Luo et al. demonstrated high repeatability with intra- and inter-assay coefficients of variation below 1%, and its application on 256 clinical samples revealed co-infection rates, underscoring the necessity of multiplex approaches for accurate epidemiological profiling [40]. Further sophistication is achieved by assays that can differentiate between PEDV genotypes G1 and G2, which is critical for understanding field strain dynamics and vaccine efficacy. A TaqMan probe-based multiplex real-time PCR developed by Zhang et al. can simultaneously distinguish PEDV subtypes G1 and G2 alongside rotavirus groups A and C, with detection limits ranging from 20 to 100 copies/μL [43]. These molecular tools, while highly sensitive, require sophisticated thermal cycling equipment and trained personnel, which can limit their deployment in point-of-care or resource-limited settings.

Isothermal Amplification and Novel Enzymatic Detection Platforms

To overcome the infrastructure demands of conventional PCR, isothermal nucleic acid amplification methods have been developed, offering rapid, field-deployable diagnostics that operate at a constant temperature. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is one of the most prominent techniques. Li et al. established an RT-LAMP method targeting the PEDV N gene, which could be completed in under one hour at 61.9°C. The assay demonstrated a limit of detection (LOD) 100-fold more sensitive than traditional RT-PCR and showed no cross-reactivity with other swine pathogens, including porcine circovirus and TGEV [75]. A further refinement involves combining LAMP with lateral flow dipsticks (LFD) for visual readout, eliminating the need for gel electrophoresis. Areekit et al. developed a duplex LAMP-LFD for the simultaneous detection of PEDV and porcine circovirus type 2 (PCV2), achieving a sensitivity 10 times greater than conventional PCR and providing results within approximately 1.5 hours using only a simple heating block [78].

Recombinase-aided amplification (RAA) and enzymatic recombinase amplification (ERA) represent another class of isothermal technologies that operate at lower temperatures (typically 37-42°C) and with shorter reaction times. Wu et al. developed a reverse-transcription RAA (RT-RAA) assay targeting the N gene, capable of detecting as few as 10 copies of PEDV DNA per reaction within 30 minutes at 41°C. This assay showed 100% specificity against a panel of nine other porcine viruses and demonstrated excellent concordance with RT-qPCR when testing clinical samples [73]. A dual ERA method established by Wu et al. enabled the simultaneous detection and discrimination of PEDV and PoRVA, achieving a detection limit of 101 copies/μL for both viruses and perfect agreement with commercial detection kits in clinical sample testing [70].

A particularly innovative approach integrates isothermal amplification with a sequence-specific endonuclease. Zhao et al. described a method combining RAA with Pyrococcus furiosus Argonaute (PfAgo), a programmable nuclease. This RAA-PfAgo cleavage assay can detect 100 copies of PEDV without cross-reactivity, and the entire process does not require sophisticated instruments. The final result can be visualized with the naked eye, making it a remarkably practical tool for on-site diagnosis in farm settings [65]. These isothermal platforms are rapidly closing the gap between laboratory-based molecular diagnostics and practical, pen-side testing.

Serological and Immunochromatographic Methods

While NAATs detect active viral RNA, serological assays are essential for determining prior immune exposure, monitoring vaccination efficacy, and conducting serosurveillance. The most advanced form is the double-antibody sandwich quantitative enzyme-linked immunosorbent assay (DAS-qELISA). Han et al. developed a DAS-qELISA using a rabbit polyclonal antibody as a capture antibody and an HRP-labeled monoclonal antibody (6C12) against the PEDV N protein as the detection antibody. This assay achieved a detection limit of 0.05 ng/mL for recombinant N protein and 10^3.02 TCID50/mL for live virus, with no cross-reactivity to other major swine viruses. When validated against anal swab samples, the DAS-qELISA showed a coincidence rate of 92.55% and 94.29% when compared to RT-PCR and commercial antigen test strips, respectively, confirming its reliability for clinical application [68].

For rapid, point-of-care screening, immunochromatographic assays, specifically colloidal gold immunochromatography assay (GICA) strips, are invaluable. Zhou et al. developed a duplex GICA strip for the simultaneous detection of PEDV and TGEV. This tool demonstrated no cross-reactivity with five other common porcine viruses and had visual detection limits of approximately 10^4 TCID50/mL for both pathogens. The strip remained stable when stored at 4°C or 25°C for 12 months, making it highly practical for field use on pig farms [66]. A further enhancement was reported by Chen et al., who utilized tris-stabilized gold nanoparticles (AuNPs) to create a sensitive lateral flow immunoassay (LFIA) for the simultaneous on-site detection of PEDV and rotavirus. This LFIA achieved LODs of 1.25 × 10^3 TCID50/mL for PEDV and 3.13 × 10^2 pg/mL for rotavirus, with a total assay time of just 18 minutes. Clinical validation showed concordance rates of 95% and 100% with RT-PCR for PEDV and rotavirus, respectively [69].

Beyond antigen detection, measuring antibody levels is critical for managing herd immunity. Hu et al. demonstrated that serum anti-PEDV IgA antibody levels in sows could serve as a valuable pre-evaluation indicator of immunization effects. Their study found that serum IgA levels correlated strongly with colostrum IgA (coefficient of 0.63), and these levels were predictive up to 21 days before parturition. This insight allows veterinarians to dynamically adjust vaccination strategies to ensure adequate passive immunity transfer to piglets [67].

Next-Generation Sequencing (NGS) and CRISPR-Based Diagnostics

The limitations of targeted NAATs are that they only detect known sequences. Next-generation sequencing (NGS), including metagenomic sequencing, provides an unbiased, comprehensive view of the entire genetic landscape of a sample. This is particularly powerful for identifying novel PEDV variants, recombinant strains, and co-infecting pathogens. For example, Qiu et al. used metagenomic sequencing to reveal that porcine kobuvirus (PKV) was the most abundant virus (58.33%) in diarrheic piglets, even exceeding PEDV (34.45%), providing pathogenic evidence for viral interactions that would be missed by conventional PCR [77]. NGS of the complete PEDV genome is essential for tracking the emergence of recombinant strains, such as the GII-a recombinant CH/HLJ/18 identified by Guo et al., which possessed unique deletions and mutations in the S protein associated with high pathogenicity [9]. Olech emphasizes that NGS, while providing highly specific results, requires significant bioinformatics infrastructure, but it is indispensable for defining the molecular epidemiology and evolution of the virus [76].

One of the most revolutionary frontiers in molecular diagnostics is the application of CRISPR-Cas systems. While not yet widely deployed for routine PEDV testing, the potential is immense. As Olech reviews, CRISPR-based platforms (e.g., Cas12a, Cas13) can be programmed to target specific PEDV nucleic acid sequences with high fidelity. After target recognition, the Cas enzyme's collateral cleavage activity can generate a detectable signal (e.g., fluorescence or colorimetric change), often achieving attomolar sensitivity. When coupled with isothermal pre-amplification, these systems combine the specificity of a sequence-specific nuclease with the simplicity of a lateral flow readout, promising a new generation of ultra-rapid, field-deployable, and highly sensitive diagnostic tools [76].

Host-Response and Metabolomic Profiling as Diagnostic Avenues

An emerging paradigm in infectious disease diagnostics is the profiling of the host's response to infection. Rather than detecting the pathogen directly, these methods analyze the host's altered proteomic, metabolomic, or transcriptomic landscape. Wang et al. performed a synergistic metabolomic and proteomic analysis of PEDV-infected porcine intestinal epithelial cells. They identified 522 differential metabolites and 295 differentially expressed proteins, with the betaine-homocysteine S-methyltransferase (BHMT) emerging as a potential key regulator. Knockdown of BHMT significantly reduced PEDV copy numbers and titers, suggesting that such host factors could serve as diagnostic biomarkers or even antiviral targets [72]. Furthermore, the discovery that Faecalibacterium prausnitzii-derived outer membrane vesicles (OMVs) increase phosphatidylcholine (PC) levels to alleviate PEDV infection, as detailed by Xing et al., opens the possibility of using specific gut microbial metabolites as indirect diagnostic indicators of infection status or gut health [1]. Single-cell RNA sequencing, as employed by Fan et al., provides an unprecedented resolution of the host response, identifying which specific cell types (enterocytes, goblet cells, tuft cells) are susceptible and how their transcriptomes shift upon viral invasion. This deep biological insight can inform the development of highly specific diagnostic signatures based on host gene expression patterns [74]. These advanced techniques are currently more suited for research and reference laboratories, but they represent the future of comprehensive, mechanism-based diagnostics for PEDV.

Vaccine Development and Immunoprophylaxis Strategies

The development of effective vaccines and immunoprophylaxis strategies against Porcine Epidemic Diarrhea Virus (PEDV) represents one of the most formidable challenges in contemporary swine veterinary medicine. Since the emergence of highly pathogenic variant strains around 2010, the global swine industry has been confronted with a pathogen that exhibits remarkable genetic plasticity, particularly within the spike (S) glycoprotein, which serves as the primary target for neutralizing antibody responses [2, 5]. The current vaccine landscape is characterized by a critical disconnect: commercial vaccines based on classical GI strains, such as the CV777 isolate, fail to confer adequate protection against the predominant GII variant strains that now circulate globally, leaving neonatal piglets vulnerable to mortality rates approaching 100% [5, 12]. This section provides an exhaustive examination of the multifaceted approaches to PEDV vaccine development, encompassing live-attenuated vaccines, inactivated vaccines, subunit vaccines, vector-based platforms, mRNA technologies, and the emerging paradigm of reverse genetics-driven rational vaccine design, alongside a critical analysis of immunoprophylaxis strategies centered on lactogenic immunity.

The Imperative for Next-Generation Vaccines: Antigenic Mismatch and Immune Evasion

The fundamental obstacle confronting PEDV vaccinology is the profound antigenic divergence between classical vaccine strains and contemporary field isolates. Epidemiological surveillance conducted across China from 2013 to 2022 revealed that all 28 epidemic strains circulating in Yunnan Province clustered within the GII genotype, sharing only 85.6% to 99.3% amino acid homology with classical strains in the S protein [4]. Similarly, analysis of 104 PEDV strains collected from 303 farms in China between 2017 and 2021 demonstrated that 68.27% belonged to the predominant G2c subgroup, with newly defined G2d strains emerging in multiple provinces [24]. This genetic drift is not merely a phylogenetic curiosity; it has direct functional consequences for vaccine efficacy. The S protein, which mediates viral attachment to host cell receptors and membrane fusion, contains the principal neutralizing epitopes, and mutations within this protein can substantially alter antigenicity [3, 6, 14]. Indeed, reverse genetics experiments have unequivocally demonstrated that substitution of the spike gene from highly virulent GII strains into the genetic background of the avirulent DR13 vaccine strain confers severe pathogenicity, with recombinant viruses inducing high mortality in 3-day-old piglets [3]. This finding underscores that the spike protein is not only a determinant of virulence but also the primary driver of antigenic variation that undermines vaccine-induced protection.

The limitations of current immunization approaches are starkly illustrated by field observations. Maternally derived antibodies elicited by inactivated vaccines cannot completely protect piglets from infection with variant strains, and the classic attenuated CV777 vaccine strain is insufficient to fully protect against contemporary PEDV variants [5]. Furthermore, the practice of feedback feeding, the intentional exposure of sows to infected piglet intestinal contents to boost immunity, carries the risk of periodic PEDV recurrence in herds and may inadvertently promote viral recombination and evolution [5]. The World Organisation for Animal Health (WOAH) recognizes PED as a significant transboundary animal disease, and the Food and Agriculture Organization (FAO) has emphasized the need for improved vaccine strategies to mitigate the economic impact on global food security and swine production systems.

Live-Attenuated Vaccines: Rational Design Through Reverse Genetics

Live-attenuated vaccines (LAVs) represent the most promising avenue for inducing robust, long-lasting protective immunity against PEDV, particularly lactogenic immunity in sows, which can be passively transferred to nursing piglets via colostrum. However, the traditional approach of serial passage in cell culture to achieve attenuation carries the risk of insufficient or unstable attenuation and may not adequately preserve immunogenicity. The contemporary paradigm for LAV development leverages reverse genetics to introduce defined attenuating mutations into the viral genome, enabling precise control over virulence while retaining the capacity to elicit protective immune responses.

Attenuation Through Deletion of Virulence Determinants

The identification of specific genetic signatures associated with virulence has provided targets for rational attenuation. Serial passage of PEDV in Vero cells and in piglets revealed that increased passage number correlates with reduced virulence and the accumulation of specific amino acid substitutions in the S protein, including changes at positions 223, 291, 317, 607, 694, 1114, and 1199, as well as reduced N-linked glycosylation [11]. More targeted approaches have focused on specific genomic deletions. Analysis of the cell culture-adapted PEDV strain AH2012/12, which had undergone over 102 passages, identified two major deletions: one within the S1 gene and a second encompassing the carboxy-terminus of the S2 gene and the start codon of ORF3 [18]. Remarkably, recombinant viruses engineered to carry only the deletion of the carboxy-terminus of the S gene were fully attenuated in piglets, exhibiting no mortality, extremely low virus shedding, and no signs of diarrhea [18]. Crucially, this deletion-bearing recombinant virus induced significantly higher IgG, IgA, and neutralizing antibody responses than a killed vaccine, and conferred robust protection against challenge [18]. This finding establishes the carboxy-terminus of the S2 domain as a critical virulence determinant and provides a viable strategy for engineering attenuated vaccine candidates.

Similarly, targeted mutations in non-structural proteins have yielded attenuated viruses with retained immunogenicity. The PEDV non-structural protein 1 (nsp1) is a key antagonist of the host interferon (IFN) response. Recombinant PEDV carrying N93A and N95A mutations in nsp1 replicated to lower titers, triggered stronger type I and III IFN responses, and was partially attenuated in gnotobiotic piglets [29]. Importantly, piglets immunized with this nsp1 mutant were protected from severe diarrhea and death upon subsequent challenge with the virulent wild-type virus [29]. Because nsp1 is conserved among alphacoronaviruses and betacoronaviruses, this approach may have broad applicability for coronavirus vaccine development.

The viral endoribonuclease (EndoU), encoded by nsp15, represents another compelling target. Mutation of the catalytic histidine residue (H226A) in EndoU abrogated its ability to suppress type I and III IFN responses in porcine epithelial cells and macrophages [31]. The EndoU-mutant PEDV exhibited impaired replication in IFN-competent cells, and in infected piglets, it demonstrated reduced viral shedding and mortality compared to the wild-type virus, yet still replicated sufficiently in the gut to induce diarrhea and presumably, protective immunity [31]. This confirms EndoU activity as a key virulence factor and provides another avenue for generating live-attenuated vaccine candidates.

Chimeric and Trypsin-Independent Vaccine Candidates

A practical challenge for PEDV vaccine production is the dependence of most field strains on exogenous trypsin for efficient propagation in cell culture, which complicates manufacturing and increases costs [26]. Through reverse genetics, a recombinant chimeric virus, rAJ1102-S2′JS2008, was constructed by replacing the S2 domain (amino acids 894-1386) of the G2 trypsin-dependent strain AJ1102 with the corresponding sequence from the trypsin-independent G1 strain JS2008 [26]. This recombinant virus propagated to high titers without trypsin supplementation and induced neutralizing antibodies against both G1 and G2 strains, representing a significant advance in vaccine manufacturability [26]. Furthermore, three key amino acid substitutions in the S protein (A605E, E633Q, and R891G) have been identified as critical for enabling efficient infection of Vero cells, altering the S2′ cleavage site and receptor binding domain structure [37]. Understanding these molecular determinants of cell adaptation provides a rational basis for designing vaccine strains that can be efficiently produced in certified cell lines.

Naturally Occurring Low-Virulence Strains as Vaccine Candidates

Not all promising vaccine candidates require genetic engineering. The naturally occurring low-virulence G2a strain CH/GXNN-1/2018, isolated from Guangxi, China, induced only mild clinical signs and no mortality in suckling piglets, despite achieving high viral titers [79]. Moreover, this strain induced cross-protective neutralizing antibodies against both homologous G2a and heterologous G2b PEDV strains as early as 72 hours post-infection [79]. Similarly, the G2d strain GS2022, while capable of causing clinical signs, resulted in no mortality in 3-day-old piglets, and recovery from diarrhea occurred within 5 days [22]. The strain NH-TA2020, belonging to the predominant G2c subgroup, was shown to stimulate high levels of IgA antibody in colostrum following oral administration to pregnant gilts, and piglets nursing these immunized gilts demonstrated significantly reduced clinical symptoms and virus shedding upon challenge with both homologous and heterologous G2d strains [24]. These strains may represent immediately deployable vaccine candidates that are already adapted to circulating field variants.

Inactivated and Subunit Vaccines: Safety and Precision

While live vaccines offer superior immunogenicity, inactivated and subunit vaccines provide enhanced safety profiles, particularly for use in pregnant sows. However, these platforms typically require potent adjuvants and multiple doses to achieve protective immunity.

Adjuvant Systems for Enhanced Immunogenicity

The immunogenicity of PEDV subunit vaccines, particularly those based on the S protein, can be substantially augmented through the use of toll-like receptor (TLR) agonists. CpG oligodeoxynucleotides (CpG ODNs) are potent stimulators of the porcine immune system via TLR9. A systematic evaluation of B-type CpG ODNs identified CpG5 as a particularly effective stimulator of porcine peripheral blood mononuclear cell proliferation and IFN-γ secretion [39]. When combined with the MF59 oil-in-water emulsion adjuvant, the CpG5 compound adjuvant demonstrated synergistic effects, eliciting earlier, more intense, and longer-lasting immune responses in a piglet model [39]. This included significantly enhanced neutralizing antibody titers and a considerable increase in the proportion of CD8+ T lymphocytes [39]. This approach holds significant promise for improving the efficacy of killed or subunit PEDV vaccines.

Novel Antigens: Expanding Beyond the Spike Protein

Although the S protein is the primary target for neutralizing antibodies, other structural proteins may contribute to protective immunity. The membrane (M) protein, the most abundant component of the viral envelope, plays a central role in virus morphogenesis and assembly. Computational modeling of the PEDV M protein 3D structure predicted four linear B-cell epitopes, six discontinuous B-cell epitopes, and numerous T-cell epitopes that are highly conserved across PEDV strains from different countries [28]. This suggests that the M protein could be a valuable component of multi-antigen subunit vaccines, potentially inducing broader cellular and humoral immune responses. Furthermore, the S2 subunit, which is more conserved than the S1 domain, harbors neutralizing epitopes. A neutralizing monoclonal antibody, 5F7, targeting the S2 protein, was shown to neutralize both genotype 1 (CV777) and genotype 2 (LNCT2) PEDV strains in vitro, confirming that the S2 subunit contains cross-protective neutralizing epitopes [82].

Viral Vector and Bivalent Vaccine Platforms

Vector-based vaccines offer the advantage of delivering heterologous antigens in the context of a live, replicating vector, often inducing robust cellular and humoral immunity. A landmark achievement in this area is the development of a genetically engineered bivalent vaccine against PEDV and porcine rotavirus A (PoRV). Using a reverse genetics system, the entire ORF3 gene in the attenuated PEDV strain YN150 was replaced with the PoRV VP7 gene, yielding the recombinant virus rPEDV-PoRV-VP7 [80]. This recombinant virus replicated with similar kinetics to the parental PEDV, stably expressed VP7, and induced both PEDV-specific and PoRV-specific neutralizing antibodies in vaccinated piglets, without causing clinical disease [80]. This approach demonstrates the feasibility of combining multiple swine enteric pathogens into a single vaccine, addressing the common clinical reality of co-infections, which have been shown to exacerbate disease severity [13, 23].

Immunoprophylaxis: The Central Role of Lactogenic Immunity

The primary goal of PEDV vaccination in a breeding herd is not to protect the sow from disease, but to induce high levels of neutralizing antibodies, particularly secretory IgA (sIgA), in the colostrum and milk for passive transfer to neonatal piglets. This is elegantly orchestrated through the gut-mammary gland-secretory IgA axis, where antigen-sensitized IgA plasmablasts originating in the gut-associated lymphoid tissue (GALT) migrate to the mammary gland and secrete dimeric IgA into colostrum [10, 24]. Oral immunization, which mimics the natural route of infection, is considered the most effective strategy for stimulating this lactogenic immune response.

Correlates of Protection: The Importance of IgA

Field studies have provided critical insights into the immune correlates of protection. Analysis of serum and colostrum from 75 parturient sows vaccinated with a specific protocol revealed that serum IgA exhibited the strongest correlation with colostrum IgA (correlation coefficient of 0.63), and colostrum IgA demonstrated the highest correlation with neutralizing antibody titers [67]. This finding has profound practical implications: measurement of serum anti-PEDV IgA antibody levels in sows can serve as a pre-evaluation indicator of immunization effects, potentially allowing veterinarians to identify sows with inadequate immunity up to 21 days prior to parturition and adjust vaccination strategies accordingly [67]. The persistence of elevated serum IgA from 21 days pre-parturition to 14 days postpartum provides a reliable window for serological monitoring.

Oral Immunization Strategies

The oral administration of live, virulent PEDV to pregnant gilts (a form of controlled exposure or feedback) has been historically used to boost lactogenic immunity, but this practice carries significant risks of uncontrolled virus spread and the introduction of new variants. A safer alternative involves the use of defined, attenuated vaccine strains. Oral administration of the G2c subgroup NH-TA2020 strain to pregnant gilts stimulated high levels of IgA antibody in colostrum, and piglets nursing these gilts were significantly protected against challenge with both homologous NH-TA2020 and heterologous G2d CH–HeB-RY-2020 strains [24]. This confirms that properly selected and administered oral vaccines can induce cross-protective lactogenic immunity. The critical role of virus-specific IgA effector and memory B cells in orally primed sows has been established as the cornerstone of effective lactogenic immunity [10].

Emerging Adjuvant and Immunomodulatory Strategies

Beyond traditional adjuvants, a new frontier in PEDV immunoprophylaxis involves harnessing the gut microbiota and host-commensal interactions to bolster antiviral defenses.

Probiotic-Derived Therapeutics

The gut commensal Faecalibacterium prausnitzii, recognized as a promising next-generation probiotic, and its outer membrane vesicles (OMVs) have been shown to mitigate PEDV infection in piglets [1]. Mechanistically, F. prausnitzii OMVs altered gut microbiota composition, enhancing the abundance of beneficial bacteria, and increased phosphatidylcholine (PC) levels. PC was identified as a key metabolite that reduced necroptosis in intestinal epithelial cells by inhibiting the RIPK1-RIPK3-MLKL signaling axis, thereby alleviating disease [1]. Similarly, supplementation with Lactobacillus rhamnosus GG (LGG) improved intestinal morphology, enhanced antioxidant capacity, and alleviated jejunal mucosal inflammation in PEDV-infected piglets, effects mediated in part through modulation of the TNF signaling pathway [44]. These findings suggest that probiotic-based strategies could be developed as feed additives to complement vaccination.

Metabolite-Based Antiviral Interventions

Short-chain fatty acids (SCFAs), particularly butyrate, which are produced by the gut microbiota, have demonstrated direct antiviral properties. Butyrate treatment of porcine intestinal epithelial cells limited PEDV replication by activating the GPR43 receptor, which in turn enhanced IFN-III (lambda interferon) production [53]. This reveals a host-microbiota-immune axis that could be pharmacologically or nutritionally targeted to enhance resistance to PEDV infection. Monolaurin, a natural compound with antiviral activity, also conferred protection against PEDV in piglets by regulating the interferon pathway, as demonstrated by proteomics analysis [81].

Milk-Derived Extracellular Vesicles

A remarkable recent discovery involves the antiviral activity of microRNAs (miRNAs) carried by small extracellular vesicles (sEVs) in porcine milk. Porcine milk sEVs inhibited PEDV replication in IPEC-J2 cells, Vero cells, and intestinal organoids, and pre-feeding of piglets with milk sEVs provided robust protection against PEDV-induced diarrhea and mortality [49]. The antiviral effect was mediated by specific miRNAs, miR-let-7e and miR-27b, which targeted the PEDV N protein and the host protein HMGB1 [49]. This suggests that milk-derived sEVs or their constituent miRNAs could be developed as a novel class of prophylactic or therapeutic agents.

Diagnostic Correlates and Surveillance for Vaccine Efficacy

The successful implementation of any vaccination program requires robust diagnostic tools to monitor immune responses and detect breakthrough infections. A novel double-antibody sandwich quantitative ELISA (DAS-qELISA) targeting the conserved nucleocapsid (N) protein demonstrated high sensitivity (detection limit of 0.05 ng/mL of recombinant N protein) and excellent concordance with RT-PCR (92.55%) and antigen detection test strips (94.29%) for detecting PEDV in clinical samples [68]. This tool is invaluable for confirming infection in vaccinated herds and for epidemiological surveillance. Serum IgA levels, as previously discussed, provide a surrogate marker for evaluating the effectiveness of vaccination protocols in sows [67]. Additionally, the high rate of co-infections observed in clinical settings, such as PEDV with porcine kobuvirus, porcine rotavirus, and Clostridium perfringens type A, underscores the importance of comprehensive diagnostic approaches and the potential need for multivalent vaccines [4, 13, 16, 23, 40, 71]. Multiplex quantitative PCR assays capable of simultaneously detecting PEDV, transmissible gastroenteritis virus (TGEV), porcine deltacoronavirus (PDCoV), and porcine rotaviruses are now essential tools for monitoring viral dynamics in vaccinated herds [16, 40].

Herd Immunity and the Four-Pillar Control Strategy

In endemic settings, where PEDV persists in farrow-to-finish herds despite vaccination, a comprehensive control strategy is necessary. In South Korea, a four-pillar approach has been advocated, consisting of: (i) biosecurity enhancement to prevent virus introduction and reduce transmission, (ii) herd immunity stabilization through strategic vaccination and exposure management, (iii) virus elimination from the environment,

Novel Therapeutic Approaches and Gut Microbiota Modulation

The intractable nature of Porcine Epidemic Diarrhea Virus (PEDV), characterized by its high genetic plasticity, rapid transmission, and the inadequacy of current vaccination strategies against emerging variant strains, has necessitated a paradigm shift in therapeutic development [2, 5, 12]. The World Organisation for Animal Health (WOAH) recognizes PED as a significant transboundary animal disease, underscoring the global economic threat it poses to swine production. While conventional vaccine development continues to pursue broadly neutralizing platforms, a parallel and increasingly promising avenue of research focuses on the direct modulation of the host's intestinal ecosystem and the identification of novel pharmacological agents that target specific viral-host interfaces. This section provides an exhaustive analysis of these cutting-edge strategies, moving beyond traditional antiviral screening to explore the intricate interplay between the gut microbiome, host metabolism, and viral pathogenesis.

Microbiome-Based Interventions: From Probiotics to Metabolite-Mediated Protection

The gastrointestinal tract is the primary battlefield for PEDV infection, and the resident microbial community plays a critical, yet often overlooked, role in determining disease outcome. Recent evidence has moved beyond simple correlations to establish causal mechanisms by which specific commensal bacteria and their products can confer protection against PEDV.

The Role of Faecalibacterium prausnitzii and Outer Membrane Vesicles (OMVs)

Among the most compelling advancements is the elucidation of the protective role of Faecalibacterium prausnitzii, a keystone commensal bacterium known for its anti-inflammatory properties in humans. In a landmark study, Xing et al. (2025) demonstrated that oral supplementation with F. prausnitzii significantly mitigated PEDV infection in a piglet model [1]. Critically, the research identified that the functional component responsible for this antiviral effect is not the bacterium itself, but its secreted outer membrane vesicles (OMVs). These nano-sized, lipid-bilayer-enclosed structures are packed with a complex cargo of proteins, metabolites, and small RNAs. The study revealed that the antiviral activity of F. prausnitzii OMVs is entirely dependent on the presence of an intact gut microbiota, as antibiotic-mediated depletion of the microbiota abolished the protective effect [1]. This finding underscores a sophisticated, indirect mechanism of action: the OMVs do not directly neutralize the virus but rather reprogram the metabolic output of the existing microbial community.

Metagenomic analysis following OMV administration showed a significant enrichment of beneficial taxa, including Prevotellamassilia timonensis and Limosilactobacillus reuteri, alongside an increase in F. prausnitzii itself [1]. Untargeted metabolomics pinpointed phosphatidylcholine (PC) as a key metabolite whose levels were dramatically elevated in the OMV-treated group. The mechanistic link was further solidified by single-cell sequencing, which demonstrated that PC treatment altered the cellular landscape of the intestinal epithelium, increasing the number of enterocytes and, most importantly, reducing necroptosis, a programmed form of necrotic cell death, in target cells. This was achieved through the suppression of the RIPK1-RIPK3-MLKL signaling axis, a core pathway of necroptosis [1]. This work provides a revolutionary framework for treating PEDV: rather than targeting the virus directly, one can administer a defined microbial product (OMVs) to reshape the gut ecosystem, elevating a specific metabolite (PC) that fortifies the intestinal barrier and prevents the catastrophic cell death that drives PEDV pathology.

Probiotic Strains and Short-Chain Fatty Acids (SCFAs)

The concept of using live probiotics to bolster intestinal defenses is further supported by studies on Lactobacillus rhamnosus GG (LGG). Xu et al. (2024) showed that LGG supplementation in PEDV-challenged piglets improved intestinal morphology, enhanced antioxidant capacity, and alleviated jejunal mucosal inflammation [44]. The protective effects were linked to the modulation of host signaling pathways, including the TNF signaling pathway and PPAR signaling pathway, which are central to inflammation and lipid metabolism [44]. This aligns with the broader understanding that probiotics can exert antiviral effects through immune modulation and reinforcement of the epithelial barrier.

Furthermore, the metabolic byproducts of gut microbiota fermentation, particularly short-chain fatty acids (SCFAs) like butyrate, have emerged as potent antiviral agents. He et al. (2023) demonstrated that butyrate limits PEDV replication in porcine intestinal epithelial cells (IPEC-J2) by activating the GPR43 receptor, a metabolite-sensing G protein-coupled receptor [53]. This activation triggers a signaling cascade that culminates in the production of type III interferon (IFN-λ), a key antiviral cytokine at mucosal surfaces [53]. This finding is particularly significant because it reveals a direct molecular link between a common microbial metabolite and the host's innate antiviral defense system, offering a dietary or prebiotic strategy to enhance resistance to PEDV.

Pharmacological Inhibition of Viral Entry and Replication

Alongside microbiome modulation, a robust pipeline of small molecules and natural compounds is being characterized for their direct antiviral mechanisms. These agents target discrete stages of the PEDV life cycle, from attachment and internalization to genome replication and virion assembly.

Targeting Viral Entry: Attachment and Internalization

The spike (S) protein, the primary determinant of viral tropism and entry, remains a prime target for antiviral intervention [3, 6]. Several natural compounds have been identified that interfere with this critical early step. For instance, Alpiniae oxyphyllae fructus polysaccharide 3 (AOFP3) was shown to competitively inhibit PEDV adsorption onto IPEC-J2 cells by blocking the interaction between the S protein and its putative receptor, porcine aminopeptidase [91]. Additionally, AOFP3 reduced viral penetration by decreasing cellular cholesterol levels, which are essential for membrane fusion and viral entry [91].

Bis-benzylisoquinoline alkaloids, such as cepharanthine (CEP), tetrandrine (TET), and fangchinoline (FAN), have demonstrated potent anti-PEDV activity by disrupting the entry process. Zhang et al. (2023) and Dong et al. (2022) independently confirmed that these compounds, particularly CEP and FAN, inhibit PEDV entry by suppressing lysosome acidification and decreasing the activity of cathepsin L and cathepsin B, host proteases required for S protein priming and membrane fusion within the endosomal pathway [88, 90]. This mechanism is analogous to that of certain broad-spectrum antivirals being investigated for other coronaviruses. Similarly, the FDA-approved anthelmintic drug niclosamide was identified through a high-throughput screen as a potent inhibitor of PEDV, specifically targeting the internalization step without affecting viral attachment [86]. The study further showed that combining niclosamide with other inhibitors of endosomal acidification produced a synergistic anti-PEDV effect, suggesting a viable combination therapy approach [86].

Luteolin, a common flavonoid, presents a multi-faceted mechanism. Wang et al. (2024) demonstrated that luteolin inhibits PEDV internalization, but intriguingly, this effect was independent of the S protein binding to porcine ACE2 (pACE2), a known receptor for other coronaviruses [83]. Instead, luteolin was shown to bind directly to and inhibit the activity of the PEDV main protease (Mpro), a critical enzyme for viral polyprotein processing, thereby blocking replication [83]. This dual mechanism of entry inhibition and protease targeting makes luteolin a particularly attractive lead compound.

Targeting Viral Replication Machinery

The viral replication complex, including the RNA-dependent RNA polymerase (RdRp) and the 3C-like protease (3CLpro), represents another Achilles' heel. The nucleoside analogue molnupiravir, which has been authorized for treating COVID-19, has shown strong inhibitory effects against PEDV in vitro. Huang et al. (2023) reported that molnupiravir inhibits PEDV RdRp activity, leading to a high frequency of lethal mutations in the viral genome, a process known as "error catastrophe" [89]. This suggests that broad-spectrum anti-coronavirus drugs developed for human health can be repurposed for veterinary applications.

Flavonoids continue to show promise as 3CLpro inhibitors. Li et al. (2024) screened a flavonoid library and identified baicalein and baicalin as efficient inhibitors of PEDV 3CLpro, with IC50 values in the low micromolar range [84]. Docking studies supported their binding to the enzyme's active site, and both compounds successfully suppressed PEDV replication in cell culture, primarily affecting the early post-entry replication stage [84]. Similarly, chrysin and naringenin were found to exert antiviral effects by interacting with both 3CLpro and the papain-like protease 2 (PLP-2), another key viral protease, highlighting the potential of targeting multiple viral enzymes simultaneously [85].

Exploiting Host Cellular Pathways for Antiviral Defense

An emerging and sophisticated therapeutic strategy involves manipulating host cellular processes that the virus hijacks for its own benefit. This "host-directed therapy" approach has a higher barrier to the development of viral resistance.

Modulating Autophagy and Ferroptosis

Autophagy is a double-edged sword in viral infections; some viruses subvert it for replication, while others are restricted by it. PEDV is no exception. Several host proteins have been identified that restrict PEDV by targeting the viral nucleocapsid (N) protein for autophagic degradation. A series of studies have converged on a common mechanism involving the E3 ubiquitin ligase MARCH8 and the cargo receptor NDP52. Host factors such as hnRNP K, RALY, PRPF19, FUBP3, and PTBP1 have all been shown to recruit MARCH8 to ubiquitinate the N protein, which is then recognized by NDP52 and delivered to autolysosomes for destruction [34, 58, 61-63]. This selective autophagy of a critical viral structural protein effectively halts viral replication. Furthermore, PTBP1 and TARDBP were also shown to induce type I interferon (IFN) production, providing a dual mechanism of direct viral protein degradation and innate immune activation [58, 60].

Conversely, the virus itself can manipulate autophagy to its advantage. PEDV infection upregulates TRIM28, which induces mitophagy (selective autophagy of mitochondria) to inhibit the JAK-STAT1 interferon signaling pathway, thereby promoting viral replication [47]. This suggests that inhibitors of TRIM28 could be a novel therapeutic target.

A completely different cell death pathway, ferroptosis, an iron-dependent form of non-apoptotic cell death, has also been implicated in PEDV infection. Li et al. (2023) and Zhang et al. (2023) demonstrated that the ferroptosis activator erastin and the downstream activator RSL3 significantly inhibit PEDV replication in Vero cells [55, 57]. The antiviral effect of RSL3 was linked to the inhibition of glutathione peroxidase 4 (GPX4), a key negative regulator of ferroptosis [55]. These findings suggest that pharmacologically inducing ferroptosis in infected cells could be a novel strategy to eliminate the viral reservoir.

Targeting Inflammatory and Stress Pathways

PEDV infection triggers a profound inflammatory response and endoplasmic reticulum (ER) stress, both of which can be therapeutically targeted. Quercetin, a well-known flavonoid, was shown to inhibit PEDV replication in vitro and in vivo by downregulating the NF-κB signaling pathway and reducing the levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-8) [87]. This was associated with a reduction in lipid droplet accumulation, which the virus uses to facilitate its replication [87]. Similarly, Buddlejasaponin IVb was found to inhibit PEDV replication and release while also suppressing the NF-κB pathway and reducing cytokine levels, thereby alleviating intestinal damage in piglets [59].

The ER stress response, specifically the PERK pathway, is activated by PEDV to create a favorable environment for replication. Zhou et al. (2023) showed that PEDV activates the PERK-CHOP-ERO1α-ROS axis, and that inhibiting any component of this pathway, with genetic tools or pharmacological inhibitors like GSK2606414 (a PERK inhibitor), significantly suppresses viral replication [51]. This identifies the PERK pathway as a druggable host target for controlling PEDV.

Harnessing Host Innate Immunity: Interferon and Beyond

The cornerstone of antiviral defense is the interferon (IFN) system, which PEDV potently antagonizes through multiple mechanisms [7, 31, 32, 41, 42]. Therefore, strategies that restore or amplify IFN signaling are highly sought after.

Direct IFN Induction and Signaling Restoration

The EndoU mutant PEDV (icPEDV-EnUmt) developed by Deng et al. (2019) serves as a proof-of-concept that disabling a viral IFN antagonist can create a highly attenuated, immunogenic virus that induces robust type I and III IFN responses [31]. This approach provides a blueprint for designing live-attenuated vaccines.

Beyond viral mutants, specific compounds can directly boost IFN production. Monolaurin, a natural compound found in coconut oil, was shown to confer a protective effect against PEDV in piglets by regulating the interferon pathway, as revealed by proteomics analysis [81]. Butyrate, as discussed, achieves this through GPR43-mediated induction of IFN-λ [53]. Furthermore, milk-derived small extracellular vesicles (sEVs) have been identified as a novel source of antiviral miRNAs. Liang et al. (2023) demonstrated that porcine milk sEVs inhibit PEDV infection in intestinal organoids and in vivo, with their cargo miRNAs, miR-let-7e and miR-27b, directly targeting the PEDV N gene and the host pro-inflammatory gene HMGB1, respectively [49]. This highlights the potential of using naturally occurring, bioactive nanoparticles as a therapeutic delivery system.

Targeting Viral IFN Antagonists

A more direct approach is to counteract the specific viral proteins that suppress IFN signaling. For example, the PEDV nsp7 protein inhibits IFN-induced JAK-STAT signaling by blocking the nuclear translocation of STAT1 [42]. Similarly, the M protein interacts with IRF7 to inhibit its activation [32]. Small molecules that disrupt these specific protein-protein interactions could restore the host's natural antiviral state. The identification of hyperoside as a compound that disrupts the interaction between the N protein and p53, thereby preventing virus-induced S-phase arrest and promoting an antiviral cellular environment, exemplifies this strategy [27].

In conclusion, the therapeutic landscape for PEDV is undergoing a profound transformation. The future of PEDV control will likely involve a multi-pronged approach: (1) microbiome-based therapies, such as F. prausnitzii OMVs or butyrate-producing prebiotics, to fortify the intestinal ecosystem from within; (2) direct-acting antivirals, like molnupiravir or baicalein, to suppress viral replication; and (3) host-directed therapies, including ferroptosis inducers or autophagy modulators, to create a cellular environment that is inhospitable to the virus. The integration of these novel strategies with improved vaccination protocols holds the greatest promise for mitigating the devastating impact of PEDV on global swine production.

References

[1] Xing J, Niu T, Yu T, Zou B, Shi C, Wang Y, et al.. Faecalibacterium prausnitzii-derived outer membrane vesicles reprogram gut microbiota metabolism to alleviate Porcine Epidemic Diarrhea Virus infection. Microbiome. 2025. DOI: https://doi.org/10.1186/s40168-025-02078-x

[2] Zhuang L, Zhao Y, Shen J, Sun L, Hao P, Yang J, et al.. Advances in porcine epidemic diarrhea virus research: genome, epidemiology, vaccines, and detection methods. Discover Nano. 2025. DOI: https://doi.org/10.1186/s11671-025-04220-y

[3] Li W, Hangalapura B, Elzen Pvd, Born Evd, Kuppeveld FVv, Rottier P, et al.. Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence. Journal of Virology. 2025. DOI: https://doi.org/10.1128/jvi.02165-24

[4] Zhu P, Yuan H, Shu X, Li X, Cui Y, Gao L, et al.. Epidemiological Study and Genetic Diversity Assessment of Porcine Epidemic Diarrhea Virus (PEDV) in Yunnan Province, China. Viruses. 2025. DOI: https://doi.org/10.3390/v17020264

[5] Lei J, Miao Y, Bi W, Xiang C, Li W, Zhang R, et al.. Porcine Epidemic Diarrhea Virus: Etiology, Epidemiology, Antigenicity, and Control Strategies in China. Animals. 2024. DOI: https://doi.org/10.3390/ani14020294

[6] Luo H, Liang Z, Lin J, Wang Y, Liu Y, Mei K, et al.. Research progress of porcine epidemic diarrhea virus S protein. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1396894

[7] Li X, Wu Y, Yan Z, Li G, Luo J, Huang S, et al.. A Comprehensive View on the Protein Functions of Porcine Epidemic Diarrhea Virus. Genes. 2024. DOI: https://doi.org/10.3390/genes15020165

[8] Peng Q, Fu P, Zhou Y, Lang Y, Zhao S, Wen Y, et al.. Phylogenetic Analysis of Porcine Epidemic Diarrhea Virus (PEDV) during 2020–2022 and Isolation of a Variant Recombinant PEDV Strain. International Journal of Molecular Sciences. 2024. DOI: https://doi.org/10.3390/ijms252010878

[9] Guo Y, Sui L, Kong D, Liu D, Gao Y, Jiang Y, et al.. Porcine epidemic diarrhea virus strain CH/HLJ/18 isolated in China: characterization and phylogenetic analysis. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-023-02233-6

[10] Jung K, Saif L, Wang Q. Porcine epidemic diarrhea virus (PEDV): An update on etiology, transmission, pathogenesis, and prevention and control. Virus Research. 2020. DOI: https://doi.org/10.1016/j.virusres.2020.198045

[11] Jermsutjarit P, Mebumroong S, Watcharavongtip P, Lin H, Tantituvanont A, Kaeoket K, et al.. Evolution and virulence of porcine epidemic diarrhea virus following in vitro and in vivo propagation. Scientific Reports. 2024. DOI: https://doi.org/10.1038/s41598-024-62875-6

[12] Zhang Y, Chen Y, Zhou J, Wang X, Ma L, Li J, et al.. Porcine Epidemic Diarrhea Virus: An Updated Overview of Virus Epidemiology, Virulence Variation Patterns and Virus–Host Interactions. Viruses. 2022. DOI: https://doi.org/10.3390/v14112434

[13] Wu S, Gou F, Meng J, Jin X, Liu W, Ding W, et al.. Porcine kobuvirus enhances porcine epidemic diarrhea virus pathogenicity and alters the number of intestinal lymphocytes in piglets.. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110100

[14] Luo J, Song C, Zhang T, Li J, Yang M, Wang H. Isolation and characterization of porcine epidemic diarrhea virus with mutations in the spike gene in China.. Virology. 2024. DOI: https://doi.org/10.1016/j.virol.2024.110224

[15] Jang G, Lee D, Shin S, Lim J, Won H, Eo Y, et al.. Porcine epidemic diarrhea virus: an update overview of virus epidemiology, vaccines, and control strategies in South Korea. Journal of Veterinary Sciences. 2023. DOI: https://doi.org/10.4142/jvs.23090

[16] Chen J, Liu R, Liu H, Chen J, Li X, Zhang J, et al.. Development of a Multiplex Quantitative PCR for Detecting Porcine Epidemic Diarrhea Virus, Transmissible Gastroenteritis Virus, and Porcine Deltacoronavirus Simultaneously in China. Veterinary Sciences. 2023. DOI: https://doi.org/10.3390/vetsci10060402

[17] Sun Y, Gong T, Wu D, Feng Y, Gao Q, Xing J, et al.. Isolation, identification, and pathogenicity of porcine epidemic diarrhea virus. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1273589

[18] Peng Q, Fan B, Song X, He W, Wang C, Zhao Y, et al.. Genetic signatures associated with the virulence of porcine epidemic diarrhea virus AH2012/12. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.01063-23

[19] Su Y, Hou YJ, Prarat M, Zhang Y, Wang Q. New variants of porcine epidemic diarrhea virus with large deletions in the spike protein, identified in the United States, 2016-2017. Archives of Virology. 2018. DOI: https://doi.org/10.1007/s00705-018-3874-y

[20] Kristen-Burmann C, Rogger P, Veiga I, Riebesehl S, Rappe JCF, Ebert N, et al.. Reverse Genetic Assessment of the Roles Played by the Spike Protein and ORF3 in Porcine Epidemic Diarrhea Virus Pathogenicity. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.01964-22

[21] Gao Q, Weng Z, Feng Y, Gong T, Zheng X, Zhang G, et al.. KPNA2 suppresses porcine epidemic diarrhea virus replication by targeting and degrading virus envelope protein through selective autophagy. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.00115-23

[22] Li L, Li B, Wang J, Liu L, Li Y, Sun S, et al.. A novel recombination porcine epidemic diarrhea virus isolated from Gansu, China: Genetic characterization and pathogenicity.. Veterinary Microbiology. 2023. DOI: https://doi.org/10.1016/j.vetmic.2023.109975

[23] Lee D, Jang G, Min K, Lee I, Won H, Yoon I, et al.. Coinfection with porcine epidemic diarrhea virus and Clostridium perfringens type A enhances disease severity in weaned pigs. Archives of Virology. 2023. DOI: https://doi.org/10.1007/s00705-023-05798-3

[24] Li X, Li Y, Huang J, Yao Y, Zhao W, Zhang Y, et al.. Isolation and oral immunogenicity assessment of porcine epidemic diarrhea virus NH-TA2020 strain: One of the predominant strains circulating in China from 2017 to 2021. Virologica Sinica. 2022. DOI: https://doi.org/10.1016/j.virs.2022.08.002

[25] He W, Bollen N, Xu Y, Zhao J, Dellicour S, Yan Z, et al.. Phylogeography Reveals Association between Swine Trade and the Spread of Porcine Epidemic Diarrhea Virus in China and across the World. Molecular biology and evolution. 2021. DOI: https://doi.org/10.1093/molbev/msab364

[26] Li M, Zhang Y, Fang Y, Xiao S, Fang P, Fang L. Construction and immunogenicity of a trypsin-independent porcine epidemic diarrhea virus variant. Frontiers in Immunology. 2023. DOI: https://doi.org/10.3389/fimmu.2023.1165606

[27] Su M, Shi D, Xing X, Qi S, Yang D, Zhang J, et al.. Coronavirus Porcine Epidemic Diarrhea Virus Nucleocapsid Protein Interacts with p53 To Induce Cell Cycle Arrest in S-Phase and Promotes Viral Replication. Journal of Virology. 2021. DOI: https://doi.org/10.1128/JVI.00187-21

[28] Rodríguez-Enríquez A, Herrera-Camacho I, Millán-Pérez-Peña L, Reyes-Leyva J, Santos-López G, Rivera-Benítez JF, et al.. Predicted 3D model of the M protein of Porcine Epidemic Diarrhea Virus and analysis of its immunogenic potential. PLoS ONE. 2022. DOI: https://doi.org/10.1371/journal.pone.0263582

[29] Niu X, Kong F, Xu J, Liu M, Wang Q. Mutations in Porcine Epidemic Diarrhea Virus nsp1 Cause Increased Viral Sensitivity to Host Interferon Responses and Attenuation In Vivo. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.00469-22

[30] Li Z, Ma Z, Li Y, Gao S, Xiao S. Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines. Microbial Pathogenesis. 2020. DOI: https://doi.org/10.1016/j.micpath.2020.104553

[31] Deng X, Geelen AGMv, Buckley A, O’Brien A, Pillatzki A, Lager K, et al.. Coronavirus Endoribonuclease Activity in Porcine Epidemic Diarrhea Virus Suppresses Type I and Type III Interferon Responses. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.02000-18

[32] Li S, Zhu Z, Yang F, Cao W, Yang J, Ma C, et al.. Porcine Epidemic Diarrhea Virus Membrane Protein Interacted with IRF7 to Inhibit Type I IFN Production during Viral Infection. Journal of Immunology. 2021. DOI: https://doi.org/10.4049/jimmunol.2001186

[33] Kirchdoerfer R, Bhandari M, Martini O, Sewall LM, Bangaru S, Yoon K, et al.. Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. bioRxiv. 2020. DOI: https://doi.org/10.1101/2020.02.18.955195

[34] Qin W, Kong N, Wang C, Dong S, Zhai H, Zhai X, et al.. hnRNP K Degrades Viral Nucleocapsid Protein and Induces Type I IFN Production to Inhibit Porcine Epidemic Diarrhea Virus Replication. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.01555-22

[35] Galvis J, Corzo C, Prada J, Machado G. Modeling between-farm transmission dynamics of porcine epidemic diarrhea virus: Characterizing the dominant transmission routes.. Preventive Veterinary Medicine. 2022. DOI: https://doi.org/10.1016/j.prevetmed.2022.105759

[36] Zhang Y, Li H, Chen X, Zhang L, Zhao Y, Luo A, et al.. Genetic Characteristics and Pathogenicity of a Novel Porcine Epidemic Diarrhea Virus with a Naturally Occurring Truncated ORF3 Gene. Viruses. 2022. DOI: https://doi.org/10.3390/v14030487

[37] Chen B, Dong S, Yu L, Si F, Li C, Xie C, et al.. Three Amino Acid Substitutions in the Spike Protein Enable the Coronavirus Porcine Epidemic Diarrhea Virus To Infect Vero Cells. Microbiology spectrum. 2022. DOI: https://doi.org/10.1128/spectrum.03872-22

[38] Niu T, Yu L, Zhao J, Zhang R, Ata EB, Wang N, et al.. Characterization and pathogenicity of the porcine epidemic diarrhea virus isolated in China.. Microbial Pathogenesis. 2022. DOI: https://doi.org/10.1016/j.micpath.2022.105924

[39] Wang Y, Liu S, Li B, Sun X, Pan Q, Zheng Y, et al.. A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus. Frontiers in Immunology. 2024. DOI: https://doi.org/10.3389/fimmu.2024.1336239

[40] Luo T, Li K, Li C, Xia C, Gao C. Development of a triplex quantitative reverse transcription-polymerase chain reaction for the detection of porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus, and porcine rotavirus A. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1390328

[41] Zhang J, Fang P, Ren J, Xia S, Zhang H, Zhu X, et al.. Porcine Epidemic Diarrhea Virus nsp7 Inhibits MDA5 Dephosphorylation to Antagonize Type I Interferon Production. Microbiology spectrum. 2023. DOI: https://doi.org/10.1128/spectrum.05017-22

[42] Zhang J, Yuan S, Peng Q, Ding Z, Hao W, Peng G, et al.. Porcine Epidemic Diarrhea Virus nsp7 Inhibits Interferon-Induced JAK-STAT Signaling through Sequestering the Interaction between KPNA1 and STAT1. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.00400-22

[43] Zhang L, Jiang Z, Zhou Z, Sun J, Yan S, Gao W, et al.. A TaqMan Probe-Based Multiplex Real-Time PCR for Simultaneous Detection of Porcine Epidemic Diarrhea Virus Subtypes G1 and G2, and Porcine Rotavirus Groups A and C. Viruses. 2022. DOI: https://doi.org/10.3390/v14081819

[44] Xu Z, Zhang Q, Wu M, Zhang Y, Li Z, Li H, et al.. Lactobacillus rhamnosus GG powder supplementation alleviates intestinal injury in piglets challenged by porcine epidemic diarrhea virus. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1371916

[45] Wang X, Tong W, Yang X, Zhai H, Qin W, Liu C, et al.. RBM14 inhibits the replication of porcine epidemic diarrhea virus by recruiting p62 to degrade nucleocapsid protein through the activation of autophagy and interferon pathway. Journal of Virology. 2024. DOI: https://doi.org/10.1128/jvi.00182-24

[46] Bao D, Yi S, Zhao L, Zhao H, Liu J, Wei Y, et al.. Porcine Epidemic Diarrhea Virus Infection of Porcine Intestinal Epithelial Cells Causes Mitochondrial DNA Release and the Activation of the NLRP3 Inflammasome to Mediate Interleukin-1β Secretion. Veterinary Sciences. 2024. DOI: https://doi.org/10.3390/vetsci11120643

[47] Li X, Yan Z, Ma J, Li G, Liu X, Peng Z, et al.. TRIM28 promotes porcine epidemic diarrhea virus replication by mitophagy-mediated inhibition of the JAK-STAT1 pathway.. International Journal of Biological Macromolecules. 2023. DOI: https://doi.org/10.1016/j.ijbiomac.2023.127722

[48] Zhou C, Liu Y, Wei Q, Chen Y, Yang S, Cheng A, et al.. HSPA5 Promotes Attachment and Internalization of Porcine Epidemic Diarrhea Virus through Interaction with the Spike Protein and the Endo-/Lysosomal Pathway. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.00549-23

[49] Liang J, Xie M, Hou L, Wang H, Luo J, Sun J, et al.. miRNAs derived from milk small extracellular vesicles inhibit porcine epidemic diarrhea virus infection.. Antiviral Research. 2023. DOI: https://doi.org/10.1016/j.antiviral.2023.105579

[50] Zhou H, Yan Y, Gao J, Ma M, Liu Y, Shi X, et al.. Heterogeneous Nuclear Protein U Degraded the m6A Methylated TRAF3 Transcript by YTHDF2 To Promote Porcine Epidemic Diarrhea Virus Replication. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.01751-22

[51] Zhou Y, Zhang Y, Dong W, Gan S, Du J, Zhou X, et al.. Porcine epidemic diarrhea virus activates PERK-ROS axis to benefit its replication in Vero E6 cells. Veterinary Research. 2023. DOI: https://doi.org/10.1186/s13567-023-01139-z

[52] Guo X, Feng Y, Zhao X, Qiao S, Ma Z, Li Z, et al.. Coronavirus Porcine Epidemic Diarrhea Virus Utilizes Chemokine Interleukin-8 to Facilitate Viral Replication by Regulating Ca2+ Flux. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.00292-23

[53] He H, Fan XG, Shen H, Gou H, Zhang C, Liu Z, et al.. Butyrate limits the replication of porcine epidemic diarrhea virus in intestine epithelial cells by enhancing GPR43-mediated IFN-III production. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1091807

[54] Li Z, Ma Z, Dong L, Yang T, Li Y, Jiao D, et al.. Molecular Mechanism of Porcine Epidemic Diarrhea Virus Cell Tropism. mBio. 2022. DOI: https://doi.org/10.1128/mbio.03739-21

[55] Li Y, Bao Y, Li Y, Duan X, Dong S, Lin J, et al.. RSL3 Inhibits Porcine Epidemic Diarrhea Virus Replication by Activating Ferroptosis. Viruses. 2023. DOI: https://doi.org/10.3390/v15102080

[56] Niu Z, Zhang S, Xu S, Wang J, Wang S, Hu X, et al.. Porcine Epidemic Diarrhea Virus Replication in Human Intestinal Cells Reveals Potential Susceptibility to Cross-Species Infection. Viruses. 2023. DOI: https://doi.org/10.3390/v15040956

[57] Zhang H, Li Y, Yang R, Xiao L, Dong S, Lin J, et al.. Erastin inhibits porcine epidemic diarrhea virus replication in Vero cells. Frontiers in Cellular and Infection Microbiology. 2023. DOI: https://doi.org/10.3389/fcimb.2023.1142173

[58] Qin W, Kong N, Zhang Y, Wang C, Dong S, Zhai H, et al.. PTBP1 suppresses porcine epidemic diarrhea virus replication via inducing protein degradation and IFN production. Journal of Biological Chemistry. 2023. DOI: https://doi.org/10.1016/j.jbc.2023.104987

[59] Sun P, Wang M, Li J, Qiu Y, Li H, Lv M, et al.. Inhibitory effect of Buddlejasaponin IVb on porcine epidemic diarrhea virus in vivo and in vitro.. Veterinary Microbiology. 2022. DOI: https://doi.org/10.1016/j.vetmic.2022.109516

[60] Dong S, Kong N, Zhang Y, Li Y, Sun D, Qin W, et al.. TARDBP Inhibits Porcine Epidemic Diarrhea Virus Replication through Degrading Viral Nucleocapsid Protein and Activating Type I Interferon Signaling. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.00070-22

[61] Dong S, Kong N, Wang C, Li Y, Sun D, Qin W, et al.. FUBP3 Degrades the Porcine Epidemic Diarrhea Virus Nucleocapsid Protein and Induces the Production of Type I Interferon. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.00618-22

[62] Zhai X, Kong N, Wang C, Qin W, Dong S, Zhai H, et al.. PRPF19 Limits Porcine Epidemic Diarrhea Virus Replication through Targeting and Degrading Viral Capsid Protein. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.01614-22

[63] Qin W, Kong N, Zhang Y, Dong S, Zhai H, Zhai X, et al.. Nuclear ribonucleoprotein RALY targets virus nucleocapsid protein and induces autophagy to restrict porcine epidemic diarrhea virus replication. Journal of Biological Chemistry. 2022. DOI: https://doi.org/10.1016/j.jbc.2022.102190

[64] Liu Y, Wang X, Wang J, Zhang J, Duan C, Wang J. Ergosterol Peroxide Inhibits Porcine Epidemic Diarrhea Virus Infection in Vero Cells by Suppressing ROS Generation and p53 Activation. Viruses. 2022. DOI: https://doi.org/10.3390/v14020402

[65] Zhao Y, Zhou C, Guo B, Yang X, Wang H. Pyrococcus furiosus Argonaute-mediated porcine epidemic diarrhea virus detection. Applied Microbiology and Biotechnology. 2024. DOI: https://doi.org/10.1007/s00253-023-12919-0

[66] Zhou J, Wu W, Wang D, Wang W, Chang X, Li Y, et al.. Development of a colloidal gold immunochromatographic strip for the simultaneous detection of porcine epidemic diarrhea virus and transmissible gastroenteritis virus. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1418959

[67] Hu Z, Li Y, Zhang B, Zhao Y, Guan R, Zhou Y, et al.. Serum IgA antibody level against porcine epidemic diarrhea virus is a potential pre-evaluation indicator of immunization effects in sows during parturition under field conditions. Porcine Health Management. 2024. DOI: https://doi.org/10.1186/s40813-024-00382-w

[68] Han W, Ma Z, Li Z, Chang C, Yuan Y, Li Y, et al.. A novel double antibody sandwich quantitative ELISA for detecting porcine epidemic diarrhea virus infection. Applied Microbiology and Biotechnology. 2024. DOI: https://doi.org/10.1007/s00253-024-13321-0

[69] Chen Y, He Z, Luo Y, Su Q, Wang Q, Wang J, et al.. Tris stabilized AuNPs based lateral flow immunochromatography for the simultaneous detection of porcine epidemic diarrhea virus and rotavirus on-site.. Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy. 2024. DOI: https://doi.org/10.1016/j.saa.2024.124670

[70] Wu Q, Liu X, Wang J, Xu S, Zeng F, Chen L, et al.. An isothermal nucleic acid amplification-based enzymatic recombinase amplification method for dual detection of porcine epidemic diarrhea virus and porcine rotavirus A.. Virology. 2024. DOI: https://doi.org/10.1016/j.virol.2024.110062

[71] Li Y, Niu J, Zhou X, Chu P, Zhang K, Gou H, et al.. Development of a multiplex qRT-PCR assay for the detection of porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus and porcine Deltacoronavirus. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1158585

[72] Wang H, Hui P, Uemoto Y, Ding Y, Yin Z, Bao W. Metabolomic and Proteomic Profiling of Porcine Intestinal Epithelial Cells Infected with Porcine Epidemic Diarrhea Virus. International Journal of Molecular Sciences. 2023. DOI: https://doi.org/10.3390/ijms24065071

[73] Wu X, Liu Y, Gao L, Yan Z, Zhao Q, Chen F, et al.. Development and Application of a Reverse-Transcription Recombinase-Aided Amplification Assay for Porcine Epidemic Diarrhea Virus. Viruses. 2022. DOI: https://doi.org/10.3390/v14030591

[74] Fan B, Zhou J, Zhao Y, Zhu X, Zhu M, Peng Q, et al.. Identification of Cell Types and Transcriptome Landscapes of Porcine Epidemic Diarrhea Virus-Infected Porcine Small Intestine Using Single-Cell RNA Sequencing.. Journal of Immunology. 2022. DOI: https://doi.org/10.4049/jimmunol.2101216

[75] Li C, Liang J, Yang D, Zhang Q, Miao D, He X, et al.. Visual and Rapid Detection of Porcine Epidemic Diarrhea Virus (PEDV) Using Reverse Transcription Loop-Mediated Isothermal Amplification Method. Animals. 2022. DOI: https://doi.org/10.3390/ani12192712

[76] Olech M. Current State of Molecular and Serological Methods for Detection of Porcine Epidemic Diarrhea Virus. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11101074

[77] Qiu M, Li S, Xiao Y, Li J, Zhang Y, Li X, et al.. Pathogenic and metagenomic evaluations reveal the correlations of porcine epidemic diarrhea virus, porcine kobuvirus and porcine astroviruses with neonatal piglet diarrhea.. Microbial Pathogenesis. 2022. DOI: https://doi.org/10.1016/j.micpath.2022.105703

[78] Areekit S, Tangjitrungrot P, Khuchareontaworn S, Rattanathanawan K, Jaratsing P, Yasawong M, et al.. Development of Duplex LAMP Technique for Detection of Porcine Epidemic Diarrhea Virus (PEDV) and Porcine Circovirus Type 2 (PCV 2). Current Issues in Molecular Biology. 2022. DOI: https://doi.org/10.3390/cimb44110368

[79] Yu K, Liu X, Lu Y, Long M, Bai J, Qin Q, et al.. Biological Characteristics and Pathogenicity Analysis of a Low Virulence G2a Porcine Epidemic Diarrhea Virus. Microbiology spectrum. 2023. DOI: https://doi.org/10.1128/spectrum.04535-22

[80] Li W, Lei M, Li Z, Li H, Liu Z, He Q, et al.. Development of a Genetically Engineered Bivalent Vaccine against Porcine Epidemic Diarrhea Virus and Porcine Rotavirus. Viruses. 2022. DOI: https://doi.org/10.3390/v14081746

[81] Zhang Q, Yi D, Ji C, Wu T, Wang M, Guo S, et al.. Monolaurin Confers a Protective Effect Against Porcine Epidemic Diarrhea Virus Infection in Piglets by Regulating the Interferon Pathway. Frontiers in Immunology. 2022. DOI: https://doi.org/10.3389/fimmu.2021.797476

[82] Liu J, Shi H, Chen J, Zhang X, Shi D, Ji Z, et al.. A New Neutralization Epitope in the Spike Protein of Porcine Epidemic Diarrhea Virus. International Journal of Molecular Sciences. 2022. DOI: https://doi.org/10.3390/ijms23179674

[83] Wang J, Zeng X, Gou J, Zhu X, Yin D, Yin L, et al.. Antiviral activity of luteolin against porcine epidemic diarrhea virus in silico and in vitro. BMC Veterinary Research. 2024. DOI: https://doi.org/10.1186/s12917-024-04053-4

[84] Li Z, Zhu L, Wang L, Huang Y, Zhang Y, Zhao D, et al.. Identification of two flavonoids antiviral inhibitors targeting 3C-like protease of porcine epidemic diarrhea virus. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1357470

[85] Gong M, Xia X, Chen D, Ren Y, Liu Y, Xiang H, et al.. Antiviral activity of chrysin and naringenin against porcine epidemic diarrhea virus infection. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1278997

[86] Wang Y, Huang H, Li D, Zhao C, Li S, Qin P, et al.. Identification of niclosamide as a novel antiviral agent against porcine epidemic diarrhea virus infection by targeting viral internalization. Virologica Sinica. 2023. DOI: https://doi.org/10.1016/j.virs.2023.01.008

[87] Gong T, Wu D, Feng Y, Liu X, Gao Q, Zheng X, et al.. Inhibitory effects of quercetin on porcine epidemic diarrhea virus in vitro and in vivo.. Virology. 2023. DOI: https://doi.org/10.1016/j.virol.2023.109923

[88] Dong S, Yu R, Wang X, Chen B, Si F, Zhou J, et al.. Bis-Benzylisoquinoline Alkaloids Inhibit Porcine Epidemic Diarrhea Virus In Vitro and In Vivo. Viruses. 2022. DOI: https://doi.org/10.3390/v14061231

[89] Huang Z, Zhou S, Yang Z, Wang Z. Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro. Viruses. 2023. DOI: https://doi.org/10.3390/v15061317

[90] Zhang C, Chen H, Sun L, Zhao P, Qi C, Yang Y, et al.. Bis-Benzylisoquinoline Alkaloids Inhibit Porcine Epidemic Diarrhea Virus by Disrupting Virus Entry. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12060845

[91] Luo Q, Zhang C, Chen Y, Chen H, Yang Y. Alpiniae oxyphyllae fructus polysaccharide 3 inhibits porcine epidemic diarrhea virus entry into IPEC-J2 cells.. Research in Veterinary Science. 2022. DOI: https://doi.org/10.1016/j.rvsc.2022.09.011